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1 INTRODUCTION 
1.1 The immune system 
The primary task of the immune system is to protect human bodies from different 
foreign pathogens like bacteria, viruses, fungi and parasites. Organs of the immune 
system are located throughout the body. The key organs are thymus and bone 
marrow, which belong to the primary organs where immature lymphocyte developed. 
Tissues like spleen, lymph nodes, tonsils, Peyer’s patches, and mucosa-associated 
lymphoid tissue belong to the secondary lymphatic organs where mature naïve 
lymphocytes are maintained and activated by antigen. The cells of the immune 
system rely on a distinct set of receptors to distinguish between self and non-self or 
altered self-structures on cells. Conceptually, the host immune system is divided into 
the innate immune system, which reacts rapidly and non-specifically when it 
encounters a pathogen, and adaptive immune system, which react slower but is 
specific for non-self-antigens (Murphy et al., 2009).  
 
1.1.1 The innate immune system 
The innate immune system serves as the first line of defense with the epithelial 
barrier and can also stimulate adaptive immune responses. It consists of a variety of 
cells and soluble molecules that cells secrete. The cells involved in the innate 
immune system include basophils, dendritic cells (DCs), eosinophils, Langerhans 
cells, mast cells, monocytes and macrophages, neutrophils and natural killer (NK) 
cells. The soluble factors that contribute to innate immunity include the soluble 
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proteins lysozyme, interferon, and complement (Galley and Webster, 1996; Merle et 
al., 2015; Van Der Vaart et al., 2012).  
The innate immune response relies on the recognition of pathogen-associated 
molecular patterns (PAMPs) through germline-encoded receptor called pattern 
recognition receptors (PRRs). When phagocytic cells like neutrophils, macrophages 
or DCs, recognize PAMPs via complementary PRRs, the PAMP bearing structure will 
be phagocytosed and a range of cytokines or chemokines will be secreted (Croce, 
2008; Murphy et al., 2009). The cytokines and chemokines released by macrophages 
in response to bacterial constituents initiate the process known as inflammation. The 
activation of complement on the bacterial cell surface by invading bacteria can also 
lead to the phagocytosis and local inflammation (Murphy et al., 2009). In addition, NK 
cells are important effector cells for the innate immune system. They can recognize 
stressed cells in the absence of self MHC (major histocompatibility complex, called 
HLA in human) and antibodies, which allow them to react much faster than other 
immune cells (Anfossi et al., 2006). The cytotoxicity of NK cells is regulated by a 
balance between activating and inhibitory signals (Mandal and Viswanathan, 2015). 
Other important cells of the innate immune system are monocytes that will be 
discussed comprehensively in Chapter 1.4. 
 
1.1.1.1 Pathogen recognition receptors (PRRs) and pathogen-associated 
molecular patterns (PAMPs) 
PRRs are receptors which are predominantly expressed on immune cells and can 
recognize a broad spectrum of common molecular motifs known as pathogen- or 
damage-associated molecular patterns (PAMPs and DAMPs) (Murphy et al., 2009; 
Tang D et al., 2012). PRRs of the innate immunity differ from that of the adaptive 
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immunity. The PRRs are categorized into four families: Toll-like receptors (TLRs), 
Nucleotide-binding oligomerization domain-like receptors (NLRs), C type lectin 
receptors (CLRs) or RIG-1 like receptors (RLRs) (Mogensen, 2009). Among those 
four families, TLRs are the best characterized. PAMPs are usually specific to micro-
organism, e.g. single- or double-stranded RNA (recognized by TLR3, 7 and 8), 
bacterial liposaccharide (LPS, recognized by TLR2 and 4), flagellin (recognized by 
TLR5) or dsDNA and unmethylated CpG DNA fragments (recognized by TLR9) 
(Kawai and Akira, 2011; Kawasaki and Kawai, 2014; Tang D et al., 2012). Ligation of 
PRR-PAMP triggers proinflammatory and antimicrobial responses by activating 
intracellular signaling pathways, e.g. kinases, adapter molecules and transcription 
factors like nuclear factor-B (NF-B), activator protein-1 (AP-1), and IFN regulators 
factors (IRFs) (Tang D et al., 2012). 
 
1.1.1.2 Toll like receptors 
TLRs are characterized by a Toll/IL-1 receptor (TIR) homology domain in the 
cytoplasmic region and a leucine-rich repeat domain extracellularly (Medzhitov, 
2001). They are expressed differently in a variety of cells, including monocytes, DCs 
as well as non-immune cells like vascular endothelial cell, adipocytes, cardiac 
myocytes and intestinal epithelial cells. There are 10 different human TLRs (12 in 
mice) (O’Neill et al., 2013). TLR3, TLR7, TLR9 are nucleic-acid receptors that are 
expressed intracellularly whereas other TLRs are expressed on the cell surface 
(Kawasaki and Kawai, 2014; O’Neill et al., 2013).  
After recognizing their corresponding PAMPs, specific signaling cascades will be 
initiated via individual TLRs based on the recruitment of a single or a specific 
combination of TIR-domain-containing adaptor protein like MyD88, TIRAP, TRIF or 
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TRAM (Kawai and Akira, 2011). TLR signaling is divided into two distinct signaling 
pathways, the MyD88-dependent and TRIF-dependent pathway. All TLRs (except 
TLR3) signal through the MyD88-dependent pathway (shaded in blue in Fig. 1). 
Mitogen-activated protein kinase as well as NF-B control the induction of 
proinflammatory cytokines and chemokines as well as the upregulation of co-
stimulatory molecules on DCs (Lawrence, 2009; Sen and Baltimore, 2013). 
Moreover, the TRIF-dependent pathway (shaded in red in Fig. 1) can induce the 
activation of IRF3 followed by the production of type I interferons. Late-phase NF-B 
can also be activated via TRIF-dependent pathway. Production of inflammatory 
cytokines requires the activation of both late and early phase NF-B (Kawai and 
Akira, 2010).  
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Figure 1: TLR signal transduction pathways. Two distinct signaling pathways, the MyD88-
dependent and TRIF-dependent pathway are grouped based on their use of the TLR 
adaptors. TIRAP conducts the signal from TLR4 to MyD88, and TRAM mediates the signal 
from TLR4 to TRIF. The TRIF/TBK1 signaling complex phosphorylates IRF3 and lead to the 
production of Interferon type I. Myddosome is formed upon TLR engagement and IRAK1 will 
be activated during its formation. IRAK1 activation induces TRAF6 activation following K63-
linked polyubiquitination on TRAF6 and TAK1. IKK complex-NF-B and MAPKs (mitogen-
activated protein kinases) will be activated upon TAK1 activation. Figure was adapted from 
Barton et al., 2003. 
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1.1.1.3 Heat shock proteins 
Heat shock proteins (HSPs) are highly conserved molecules that are constitutively 
present or can be induced upon exposure to a variety of environmental stress 
conditions, including heat shock, oxidative stress, nutritional deficiencies, ultraviolet 
irradiation, viral or bacterial infection, inflammation and chemicals (Ciocca and 
Calderwood, 2005; Colaco et al., 2013). Tumor microenvironment is characterized by 
hypoxia, low pH, altered metabolism and high demand of new blood vesicle 
formation (Reynolds et al., 1996). Therefore, various HSPs are shown to be highly 
expressed in tumor cells or tissues, such as HSP27 in gastric cancer (Baba et al., 
2013), HSP70 in breast and oral cancer (Kaur et al., 1998; Patricia et al., 2000), 
HSP90 in breast and endometrial cancer (Komatsu, 1996; Yano et al., 1999). 
Besides, HSPs can be actively released by tumor cells into the extracellular milieu 
directly or via extracellular vesicles (Liu et al., 2015; Reddy et al., 2018; Vicencio et 
al., 2015).  Cells undergoing necrotic lysis can also secrete HSPs in an autocrine, 
paracrine, or endocrine manner, in response to cytotoxic T lymphocytes (CTL), NK 
cells, or viral infections (Colaco et al., 2013).  
HSPs are categorized into several families based on their molecular weight including 
the small heat shock protein families, Hsp40, Hsp60, Hsp70, Hsp90, Hsp100 
(Prohaszka, 2003; Wu et al., 2017). HSPs are also called molecular chaperones, 
which ubiquitous chaperone nascent polypeptides so to stabilize newly synthesized 
or improperly folded protein (Saibil, 2013). It has been shown that some heat shock 
proteins, e.g. Hsp70, Hsp90, gp96 and calreticulin, could serve as important 
adjuvants in the stimulation of immune response based on their ability to bind not 
only whole proteins but also peptides (Srivastava et al., 1994). Within last decades, 
more HSPs are shown to have both stimulatory and regulatory roles in innate and 
adaptive immune responses (Prohaszka, 2003). 
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1.1.1.4 HSP90 family 
As one of the most abundant proteins in cells, HSP90 family accounts for 1–2% of all 
cellular proteins in most cells under non-stress conditions (Chen et al., 2006). Many 
oncogenes are client proteins of HSP90, including (i) tyrosine-kinase receptors like 
HER2, mutant EGFR, c-KIT, VEGFR and IGF1R, (ii) signal-transduction proteins like 
NRAS, mutant BRAF, BCR–ABL, AKT and IKK, (iii) transcripti-RAon factors like 
HIF1α and mutant P53, (iv) cell-cycle regulatory proteins like CDK4, CDK6, PMYT1, 
cyclin D and mutant RB, (v) anti-apoptotic proteins like APAF1, survivin, RIPK1, 
BCL2 or others proteins like hTERT, FAK1, MMP2 (matrix metalloproteinases) 
(Garcia-Carbonero et al., 2013).  
Expression pattern of HSP90 was determined in a large cohort of melanoma 
patients. Higher HSP90 expression was shown in melanoma tissues compared to 
nevi and was associated with a disease progression (Liu and Zhang, 2008). 
Moreover, Mbofung et al. (Mbofung et al., 2017)  found that T-cell-mediated killing of 
patient-derived human melanoma cells was enhanced in vitro by the application of 
HSP90 inhibitor ganetespib that was also observed to potentiated to the responses to 
anti-CTLA4 and anti-PD1 therapy in mouse model. Nowadays, promising effects in 
clinical trials have been shown with the application of HSP90 inhibitors (Eroglu et al., 
2018; Garcia-Carbonero et al., 2013; Mbofung et al., 2017; Trepel et al., 2010). 17-
Demethoxygeldanamycin (17-AAG), a geldanamycin derivative, is a natural product 
that binds to HSP90 and inhibits its activity. In 2011 in the frame of phase II clinical 
trial, 17-AAG was applied together with trastuzumab (anti-HER2 antibody) in HER2-
positive breast cancer patients with metastasis who were previously resistant to 
trastuzumab (Modi et al., 2011). Those findings provide proofs for HSP90 to serve as 
a therapeutic target in the treatment of cancer. 
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1.1.2 The adaptive immune system 
As mentioned above, pathogens can active the innate immune response and then 
work together to stimulate the adaptive immune system. The major task for the 
adaptive immune system is to fight long-lasting infections and to create 
immunological memory that leads to protective immunity on a second encounter with 
the same pathogen (Goldszmid and Trinchieri, 2012; Murphy et al., 2009). The 
adaptive immune system is comprised by T cells and B cells which are responsible 
for T-cell-mediated immune responses and antibody responses respectively. Unlike 
B lymphocytes, which can recognize extracellular pathogens and secrete antibodies 
for systemic response, T cells can only recognize intracellular pathogens and act at 
short range (Bonilla and Oettgen, 2010; Kumar et al., 2018). T cells are activated by 
the recognition of peptide: MHC complexes displayed on the surface of antigen 
presenting cells (APCs) like DCs (Bonilla and Oettgen, 2010; Murphy et al., 2009). 
 
1.1.2.1 T cells  
T cells can be divided into three subsets: cytotoxic (CD8+ CTL), helper (TH cells) and 
regulatory T cells (Tregs). The activation of T cell requires three signals. The first 
signal which has already mentioned earlier is the requirement of the presence of 
peptide: MHC. T cell expressing CD4 co -receptor binds to class II MHC proteins, 
whereas cytotoxic T cells that express CD8 co-receptor binds to class I MHC 
proteins. Co-stimulatory proteins like B7.1 (CD80) or B7.2 (CD86) and tumor 
necrosis factor (TNF) families are needed for signal two. Those proteins are typically 
expressed on activated DCs. The binding of them to other receptors on T cell surface 
initiate the second signal. The third signal is inflammatory cytokines such as 
interleukin 12 (IL-12) or type I interferons (type I IFN). 
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After activation, cytotoxic T cells can directly kill the infected cells either by releasing 
perforin which then polymerizes in the target cell plasma membrane to form 
transmembrane channels, or through the binding of Fas ligand on cytotoxic T cell 
surface to Fas, which is a transmembrane receptor protein on the target cells (Barry 
and Bleackley, 2002; Murphy et al., 2009). The binding will active a death-inducing 
caspase cascade that leads to apoptosis of target cells. Helper T cells can secret a 
variety of cytokines and display a broad spectrum of co-stimulatory proteins on their 
surface to help macrophages to destroy the microbes or activate B cells to make 
antibodies against the microbes (Oh and Hwang, 2014). On the other hand, similar 
strategies are used by Tregs to inhibit the function of cytotoxic T cells, helper T cells 
and DCs to keep homeostasis in human body (Murphy et al., 2009). 
1.1.2.2 Negative feedback regulation of T cells 
Co-inhibitory receptors, together with the above mentioned co-stimulatory receptors 
like CD28 and ICOS, maintain homeostasis through a continuous balance between 
positive and negative signaling. Co-signaling is controlled through either the 
modulation of cell surface expression or the differential expression patterns of 
receptor-ligand pairs function (Chen and Flies, 2013). CTLA-4 and PD-1 are the best-
studied co-inhibitory receptors. 
1.1.2.3 Programmed death-1 receptor/ Programmed death-1 ligand 1 
PD-1 (CD279), a type I transmembrane protein, was first identified in 1992 (Ishida et 
al., 1992). It contains two phosphorylation sites located in an immunoreceptor 
tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch 
motif (ITSM) of the intracellular tail which is important for the inhibitory function of 
PD-1 (Blank and Mackensen, 2007; Ishida et al., 1992). The ligands for PD-1 are 
programmed death ligand-1 (PD-L1, CD274) and programmed death ligand-2 (PD-
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L2, CD273) (He et al., 2004). When PD-1 binds to its ligand, intracellular tyrosinases 
in ITIM and ITSM are phosphorylated and an inhibitory signal is delivered to T cells 
followed by a decreased proliferation and cytokine production (Keir et al., 2008). 
PD-L1 is widely expressed on a variety of APCs, non-hematopoietic cells and non-
lymphoid organs like lung, heart, placenta and liver whereas the expression of PD-L2 
is restricted to macrophage and DCs (Keir et al., 2008). Regulator of PD-L1 were 
widely investigated within last ten years. Of note, inflammatory signaling, oncogenic 
signaling, microRNA, genetic alteration and post-translational regulation are found to 
be main players for PD-L1 up or down regulation (Sun et al., 2018). Among them, 
IFN-γ was described to be a strong inducer of PD-L1 acting mainly via the 
JAK/STAT1/interferon regulatory factor (IRF) 1 pathway in various tumor types, 
healthy tissues and immune cells (Brown et al., 2003; Dong et al., 2002; Sheikh et 
al., 2010; Shi, 2018). In addition to IFN-γ, other cytokines like TNF-α, epidermal 
growth factor (EGF), IL-4, IL-17, IL-27 were also shown to be important players in 
regulating PD-L1 expression. Furthermore, the ligands of TLR can also induce the 
expression of PD-L1. For instance, PD-L1 expression could be strongly upregulated 
via poly(I:C)/TLR3 signaling in neuroblastoma cells and LPS/TLR4 signaling in 
bladder cancer cells (Boes and Meyer-Wentrup, 2015; Qian et al., 2008; Shi, 2018). 
 
1.2 Tumor immunology 
Cancer is characterized by the growing of cells in an abnormal uncontrolled manner 
induced by mutations in protooncogenes and tumor suppressor genes that control 
crucial cell functions, particularly growth and survival (Hahn and Weinberg, 2002). 
These alterations provide antigens that the adaptive immune system can recognize 
to distinguish the cancer cells from normal cells. In 1957, Burnet and Thomas 
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formulated the theory of cancer immunosurveillance and proposed that 
lymphocytes act as sentinels in recognizing and eliminating continuously arising, 
nascent transformed cells (Burnet, 1957; Dunn et al., 2002). Over the past two 
decades researchers have shown that the immune surveillance is only a part of the 
story, and the concept “cancer immunoediting” consisting of three phases 
(elimination, equilibrium and escape) has been proposed by Schreiber et al. (Mittal et 
al., 2014; Schreiber et al., 2011) (Fig. 2).  
 
 
 
Figure 2: The three E’s of cancer immunoediting. Schematic representation of 
interactions between tumor cells with immune system that are divided into three phases: 
elimination, equilibrium and escape. Figure was adapted from Schreiber et al.,(Schreiber et 
al., 2011). 
 
   Introduction 
 
12 
 
1.2.1 Tumor immunoediting 
The first phase of immunoediting is the elimination phase. During the proliferation of 
tumor cells, inflammatory signals will be released, and innate immune cells will be 
recruited to inflammatory lesions to affect tumor cells. DCs are actived by pro-
inflammatory cytokins released by innate immune cells or DAMPs released by dying 
tumor cells. Those DCs further induce the adaptive anti-tumor immune responses 
(Dunn et al., 2002, 2006; Schreiber et al., 2011). Various effector molecules are 
shown to be important for the elimination phase like IFN-γ, perforin, Fas/FasL and 
TRAIL. If the tumor cells are completely destructed, the immunoediting concept ends 
at this point. 
Equilibrium is a phase when some tumor cell variants co-exist with the effector cells 
of the immune system in a functional state of dormancy. Genomic instability like 
nucleotide-excision repair instability (NIN), microsatellite instability (MIN), and 
chromosomal instability (CIN) has the potential to reduce the immunogenicity of 
tumor variants (Dunn et al., 2002). Moreover, some of those will display an enhanced 
capacity to grow in an unlimited immune selecting environment, which enable tumor 
cell variants eventually resist the host’s immunological sieg (Dunn et al., 2004). The 
balance between the immune system and the developing tumor during the 
equilibrium phase controls tumor outgrowth. The existence of an equilibrium phase 
was shown in both mouse and human. Immunocompetent C57BL/6 mice were 
treated with low dose 3’-methylcholanthrene (MCA) ,and no apparent tumor was 
detected. However, upon antibody-mediated depletion of IFN-γ and T cells, half of 
the animals quickly developed tumors at the site of the MCA treatment (Koebel et al., 
2007). In patients, circulating, disseminated tumor cells were still detectable in breast 
cancer patients who were free of clinically detectable tumor 20 years after treatment 
(Meng et al., 2004). In some cases, the selected tumor cell variants are able to 
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suppress the anti-tumor immune response which further result in the outgrowth of 
clinically apparent cancers. At this point, cancer immunoediting enters the escape 
phase. 
Many mechanisms are shown to mediate the escape phase, including loss of 
antigenicity, immunogenicity or immunosuppressive micorenvironment. As mentioned 
earlier, genetic alterations can lead to reduced antigenicity of tumor variants through 
loss of tumor antigen expression. This can arise due to : (i) absence of strong tumor 
antigens, (ii) loss of MHC class I, class I-like, or co-stimulatory molecules, or (iii) loss 
of antigen processing function (Schreiber et al., 2011). tumor cells could escape also 
via the induction of resistance or survival by activating pro-oncogenic transcription 
factors like STAT3 or the upregulation of anti-apoptotic molecure BCL-2 (Catlett-
Falcone et al., 1999; Schreiber et al., 2011). Moreover, tumors, which retain sufficient 
antigenicity for immune recognition can escape elimination due to the loss of 
immunogenicity. Upregulation of the immunoinhibitory molecule PD-L1 on malignant 
cells and surrounding stroma cells, or negative regulatory markers that are 
expressed on the tumor-infiltrating lymphocytes (e.g. PD-1, LAG-3, TIM-3, VISTA, 
CD244, CD160, and BTLA) are the main driving forces of the immunogenicity 
reduction (Beatty and Gladney, 2015; Dunn et al., 2002; Schreiber et al., 2011). Of 
note, the development of an immunosuppression within the tumor microenvironment 
may also facilitate the escape phase. Immunosuppressive micorenvironment is 
comprised of regulatory immune cells and soluble factors such as vascular 
endothelial growth factor (VEGF), TGF-, galectin, or indoleamine 2,3-dioxygenase 
(IDO). Myeloid-derived suppressor cells (MDSCs) were shown to be crucial in 
inhibiting host-protective antitumor responses (Kumar et al., 2016; Umansky et al., 
2016). 
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1.3 Myeloid-derived suppressor cells (MDSCs) 
In the past few decades, accumulating evidence has demonstrated that MDSCs 
belong to the major regulators of the immune system in various diseases, especially 
in cancer (Condamine et al., 2015; Dolcetti et al., 2008; Hanahan and Coussens, 
2012; Medzhitov et al., 2011; Umansky et al., 2014). Therefore, targeting MDSC 
becomes an important strategy of cancer immunotherapy. MDSCs represent a 
heterogeneous population of myeloid cells and can be identified by various markers 
in human and mouse. Polymorphonuclear (PMN)- and monocytic (M)-MDSC are two 
major subsets defined in tumor-bearing mice as CD11b+Ly6G+Ly6Clo/- and 
CD11b+Ly6G-Ly6Chi respectively. In human peripheral blood mononuclear cells 
(PBMC), PMN-MDSC are characterized as CD11b+HLA-DR-/loCD14-CD15+ or 
CD11b+CD14-CD66b+ and M-MDSC as CD11b+HLA-DR-/loCD14+CD15-. Early-stage 
MDSCs (e-MDSC) are defined as Lin− (including CD3, CD14, CD15, CD19, CD56) 
HLA-DR−CD33+ cells, however the mouse equivalent is still not identified (Bronte et 
al., 2016;). Under various pathological conditions like cancer, chronic inflammation 
and infection and autoimmune diseases, myeloid-cell progenitors will differentiate 
into MDSCs (instead of the maturation into DCs, macrophages or granulocytes) and 
will acquire immunosuppressive function (Gabrilovich and Nagaraj, 2009; Parker et 
al., 2015). 
1.3.1 Expansion, activation and recruitment of MDSCs 
Numerous inflammatory factors produced in the tumor microenvironment by tumor 
cells and immune cells or fibroblasts are involved in the expansion and activation of 
MDSC, including prostaglandin E2 (PGE2), cyclooxygenase 2 (COX-2), growth 
factors like VEGF, granulocyte-macrophage colony-stimulating factor (GM-CSF), 
granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor 
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(M-CSF), stem cell factor (SCF), TGF-β, tumor necrosis factor (TNF)-α, S100A9 
and/or S100A8, cytokines like IL-1β, IL-6, and IL-10 as well as TLR ligands 
(Gabrilovich and Nagaraj, 2009; Marvel and Gabrilovich, 2015; Parker et al., 2015; 
Ugel et al., 2015; Wesolowski et al., 2013). 
MDSCs are shown to be accumulated in tumor tissues of mice and patients with 
melanoma, prostate, lung, breast, gastric, ovarian and colorectal cancer (Adah et al., 
2016; Coosemans et al., 2016; Du Four et al., 2015; Gebhardt et al., 2015; Idorn et 
al., 2014; Limagne et al., 2016; Su et al., 2017; Zoglmeier et al., 2011). Chemokines 
and C-C motif chemokine receptors are the main driver for the migration of MDSCs 
to tumor tissue. For instance, C-C motif chemokine ligand (CCL) 2 and its receptors 
C-C chemokine receptor type (CCR) 2, CCR-4, and CCR-5 have been described to 
play a pivotal role for both M-MDSC and PMN-MDSC migration (Chun et al., 2015; 
Lesokhin et al., 2012; Umansky et al., 2017). Furthermore, there are evidence 
showing that the interaction of CCR5 and its ligands CCL3, CCL4, CCL5 (Schlecker 
et al., 2012; Tang et al, 2015; Umansky et al., 2017), other chemokines like CXCR-
CXCL12 (Obermajer et al., 2011), CXCR2-CXCL1 (Wang et al., 2017), CXCR2-
CXCL2 (Zhang et al., 2017) and CCL15 (Inamoto et al., 2016; Itatani et al., 2013) are 
of great importance in the recruitment and expansion of MDSCs.  
1.3.2 Immunosuppressive activity mediated by MDSCs 
MDSC-induced immunosuppression is mediated by a variety of mechanisms. Based 
on previous publication in mouse and human, main mechanisms could be 
summarized as follows (Groth et al., 2018; Fig. 3): a) induction of 
immunosuppressive cells like M2 macrophages and Tregs by IL-10 and IFN-γ, b) 
impaired homing of effector T lymphocytes especially CD8+ T cells via 
downregulation of the cell adhesion molecule L-selectin, CD162 and CD44, c) 
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production of reactive oxygen species (ROS) and nitric oxide (NO), which can induce 
the expression of immunosuppressive molecule like Cox-2, hypoxia-inducible factor 
1-alpha (HIF-1α) and arginase 1 (ARG1), d)depletion of metabolites critical for T cell 
functions such as L-arginine, e) activation of ectoenzymes CD39 and CD73, mainly 
in a HIF-1α-dependent manner, which regulate adenosine metabolism, and f) 
expression of negative immune checkpoint molecules like PD-L1. Through those 
mechanisms, activated MDSC can suppress the function of various cells in both 
innate immune system like NK cells (Elkabets et al., 2010) and adaptive immune 
system like T cells (Bronte et al., 2016; Ghansah, 2012) and B cells (Li et al., 2014). 
In tumor microenvironment, MDSC can promote tumor invasion and metastasis by 
the secretion of different soluble factors such as MMPs, proangiogenic factors like 
VEGF, TGF-β, DAMPs etc. (Meyer et al., 2011; Talmadge and Gabrilovich, 2013). 
VEGF can stimulate tumor neovascularization, whereas MMPs (especially MMP9) 
facilitate invasion and metastasis (Umansky et al., 2016). The expansion of MDSCs 
can be promoted by DAMPs such as S100A8/A9, leading to an influx of inflammatory 
molecules within the tumor microenvironment (Parker et al., 2015). 
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Figure 3: Main mechanisms of immunosuppression mediated by myeloid-derived 
suppressor cells (MDSCs). a) induction of immunosuppressive cells, b) impairment of the 
recruitment of effector lymphocytes, especially CD8+ T cells, c) production of ROS and NO d) 
depletion of metabolites critical for T cell functions such as L-arginine, e) generation of 
ectoenzymes CD39 and CD73, f) expression of negative immune checkpoint molecules like 
PD-L1. The figures was adapted from Groth et al., 2018.  
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1.4 Monocytes 
Monocytes are generated in the bone marrow from hematopoietic progenitor cells 
and play a critical role in pathogen challenge and homeostasis. Under normal 
condition, monocytes circulate in the bloodstream only for few days before 
undergoing spontaneous apoptosis (Fahy et al., 1999). Under pathological conditions 
such as infection, inflammation or cancer, monocytes can be rapidly recruited to 
tissues where they differentiate into macrophages, DCs or MDSCs who have a 
longer life span (Parihar et al., 2013). In human, circulating monocytes are divided 
into three subgroups based on their phenotype and function (Gordon and Taylor, 
2005; Ziegler-Heitbrock, 2015). The classical monocytes (approx. 90–95%) are 
defined as CD14++CD16− cells, whereas the intermediate and non-classical 
monocytes are CD14++CD16+ and CD14+ CD16++ respectively (Ziegler-Heitbrock et 
al., 2010). 
 
1.4.1 The role of monocytes in innate immunity 
A complex network of survival and death signals are involved in controlling monocyte 
life span. Monocytes and macrophages express a broad range of TLRs (Hawn and 
Underhill, 2005). In response to PAMPs or DAMPs, monocytes produce various pro-
inflammatory cytokines like IL-1β, TNF-α via TLR signaling (Goyal et al., 2002). 
However, when inflammation occurs, anti-inflammatory cytokines like TGF-β, IL-10, 
IL-13, IL-4 and PGE2 will also be produced by classical monocytes to counteract 
ongoing inflammation(Yang et al., 2014). As a result of respiratory burst, an 
activation of monocytes causes a massive generation of ROS. Elevated monocyte 
chemoattractant protein-1 (MCP-1/CCL2) production is also known to be a crucial 
characteristic of monocyte activation (Parihar et al., 2010). 
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1.4.2 Regulation of monocyte death and survival  
A complex network of survival and death signals controls the life span of monocytes 
(Fig. 4). The initiation of monocyte apoptosis is regulated by intrinsic (also called 
the mitochondrial pathway)  and extrinsic  pathways. Some factors like Fas 
receptors, TNF receptor, caspases, BAX, BID, BAK, or BAD are known to promote 
apoptosis while others play crucial role in inhibiting apoptosis. Those negative 
regulators can be categorized into anti-apoptotic factors such as  Bcl-2, Bcl-XL, Mcl-1 
and survivin or pro-survival factors like cFLIP, FADD, Akt, and NF-B. 
 
 
 
Figure 4: Signaling networks, regulating the life span of monocytes and macrophages. 
Figures was adapted from Parihar et al., 2010.  
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1.5 Malignant melanoma 
Melanoma is a deadliest form of skin cancer. Worldwide, 1.7 % of primary malignant 
cancers (excluding nonmelanoma skin cancer) are newly diagnosed as cutaneous 
melanoma and account for 0.7 % of all cancer annually (Schadendorf et al., 2018). 
Melanoma originates from the pigment-producing melanocytes in the skin. In early 
stages, melanoma is highly localized and can be treated by surgery and adjuvant 
therapy. However, melanoma rapidly becomes life-threatening once it developed into 
reginal metastases. The preferential sites of metastasis are reginal lymph nodes, 
lung, liver, bone and brain. Since 2011, melanoma treatment has been revolutionized 
with the approval of tyrosine kinase inhibitors, immune check point inhibitors and 
talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) (Pol et al., 2016; 
Schadendorf et al., 2018).  
1.5.1 Melanoma treatment 
1.5.1.1 Target therapy 
A genomic classification of melanoma includes four subtypes: B-Raf, Ras, NF1 and 
triple wild-type subtypes, since the occurrence and progression of melanoma are 
closely correlated with those mutations (Akbani et al., 2015). The BRAF, RAS 
(N/H/K) and NF1 subtypes are observed in more than 90% of cutaneous melanoma 
patients (Akbani et al., 2015). Those mutations located at different levels of the 
MAPK/Extracellular signal-regulated kinase (ERK) pathway remain the most 
frequently drug-target pathway in melanoma. B-Raf and MAPK/Erk kinase (MEK) 
inhibitors considerably improved the treatment of melanoma but failed in the retention 
of a durable response and drug resistance.  
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1.5.1.2 Immunotherapy with immune check point inhibitors 
Immunotherapy has transitioned from interferon and interleukin cytokine-based 
treatment to antibodies against CTLA-4 and PD-1. Notably, the application of anti-
CTLA-4 and anti-PD-1 therapy allowed the handling of wide-type B-Raf melanomas 
and leads to a dramatic improvement in the prognosis and survival of advanced 
melanoma patients.  
Nivolumab or Pembrolizumab, monoclonal antibodies against PD-1, were approved 
in 2014 and are widely used in the treatment of melanoma, small cell lung cancer, 
renal cell carcinoma, lymphoma and other cancer types. Patients treated with anti-
PD-1 antibodies showed significant clinical benefits and prolonged survival. However, 
a substantial percentage of patients do not respond to this treatment. Higher 
mutation load (Hugo et al., 2017) and PD-L1 expression on tumor cells (Iwai et al., 
2002; Tumeh et al., 2014) were shown to be associated with better outcomes. 
However, clinical responses to anti–PD-1 therapy in PD-L1–negative tumors also 
have been observed (Dutriaux et al., 2014; Powles et al., 2014). Predictive 
biomarkers for the clinical response and characterization of resistance mechanisms 
to tumor immunotherapy are necessary to have a better guidance of clinical decision. 
 
1.6 Extracellular vesicle 
Extracellular vesicles (EVs) are membraned-bound vesicles with complex cargos 
including lipids, proteins, DNA, mRNA and noncoding RNA (ncRNA) like miRNA. EVs 
are classified into exosomes (40-150 nm), microvesicles (MVs, 200-500 nm) and 
apoptotic bodies (1-2 μm) based on their size, origin, biological function and 
biogenesis pathway (Syn N et al., 2016; Pitt et al., 2016). Exosomes are released by 
multivesicular bodies (MVBs) through endosome membrane whereas microvesicles 
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bud directly from the plasma membrane. In addition, cells undergoing apoptosis are 
dissociated into various sizes of vesicles that are known as apoptotic bodies (Maas 
et al., 2016; Pitt et al, 2016). The size of EV subsets are overlapping and there is to 
date no consensus over the specific markers for EV subpopulation. However current 
purification approaches for EVs are mainly size or density based, which does not 
allow to talk about a distinct EV subpopulation.  
In 2018, a nomenclature recommendation by the International Society for 
Extracellular Vesicles is offered, which claims that operational terms of EV subtypes 
should be used, either refer to physical characteristics, biochemical composition or 
descriptions of conditions or cell of origin (Théry et al., 2018). EVs can be divided into 
“small EV” (sEV) and “medium/large EV” (m/l EV) based on size with ranges defined 
< 200nm (small) or > 200nm (large and/or medium) respectively or low, middle, high 
density EVs with each range defined. On the other hand, the description based on 
biochemical composition e.g. as CD63+/CD81+ EVs or Annexin A5-stained EVs, can 
also be used. Moreover, EVs purified under hypoxia, irradiation, injury, cellular stress 
or EVs secreted by a specific cell type like podocyte EVs, large oncosomes are 
acceptable with a clear description (Théry et al., 2018). 
Several mechanisms have recently been identified to be essential for EV biogenesis 
(Fig. 5). The best characterized mechanism is the recruitment of the endosomal 
sorting complex required for transport (ESCRT) machinery to recognize and sort 
ubiquitinated proteins into intraluminal vesicles (ILVs) (Antonov and Stulova, 2013; 
Maas et al., 2017). Accessory proteins are required for proper function of the ESCRT 
pathway including programmed cell death 6 interacting protein (PDCD6IP; also 
known as ALIX) and tumor susceptibility gene protein 101 (TSG101) (Maas et al., 
2017; Xu et al., 2018; Zaborowski et al., 2015). Pathways that are ESCRT-
independent can also occur (e.g., synthesis of ceramide to induce vesicle curvature 
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and budding) (Antonov and Stulova, 2013; Maas et al., 2017; Van Niel et al., 2018). 
EVs can be taken up through different mechanisms, including i) the ligand-receptor 
interaction, ii) a direct release of EV contents (nucleic acids, proteins, lipids) in the 
extracellular space, iii) Rab GTPases dependent EV-plasma membrane fusion 
(including RAS- related protein RAB7A, RAB11, RAB27A, RAB27B, and RAB35) or 
iv) uptake by endocytosis then further fused with endosomal membrane (El 
Andaloussi et al., 2013; Van Niel et al., 2018). 
 
Figure 5. Extracellular vesicles: biogenesis and interaction with target cells. EVs can 
activate recipient cells via deliver transcription factors, oncogenes, non-coding regulatory 
RNAs (such as microRNAs) mRNAs into them. This activation can also be mediated by a 
direct binding of cell surface receptors via protein and lipid ligands. EVs can directly activate 
cell surface receptors via protein and bioactive lipid ligands, transfer cell surface receptors or 
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deliver effectors including transcription factors, oncogenes and infectious particles into 
recipient cells. EVs can also regulate immune response by transfer MHC molecules and 
antigens and are highly involved in antigen presentation. Figures was adapted from El 
Andaloussi et al., 2013. 
   
 
 
1.6.1 Tumor-derived extracellular vesicles 
The crosstalk between cells in tumor microenvironment are mediated by direct cell-
cell contact locally or through the secretion of EVs and soluble factors like cytokines, 
chemokines or growth factors (Gajewski et al., 2013; Ge et al., 2012).  The secretion 
of EVs is particularly active in proliferating cells like cancer cells (Whiteside, 2016). 
Emerging evidence suggests tumor-derived EVs can promote the progression, 
invasion and metastasis of cancers by various mechanisms (Théry et al., 2006).  
Firstly, oncogenic molecules such as mutated proteins, fusion gene mRNAs, and 
oncogenic lncRNAs, can be transferred to tumor microenvironment. It was shown 
that the delivery of epidermal growth factor receptor variant III (EGFRvIII) to 
EGFRvIII-negative cancer cells by glioblastoma EVs result in the acceleration of 
cancer growth (Al-Nedawi et al., 2008). In parallel, tumor EVs can promote tumor 
progression through the interaction with endothelial cells, inducing their proliferation 
and activating angiogenesis-related gene expression in those cells (Nazarenko et al., 
2010; Skog et al., 2012). Tumor self-promoting behavior can also be mediated via 
the reprograming of normal fibroblast into myofibroblasts by the uptake of tumor EVs, 
containing TGF-β1, or by the enhancement of fibroblast migration, which may further 
contribute to local invasion and pre-metastatic niche formation (Morello et al., 2013; 
Sánchez et al., 2015; Webber et al, 2010).  
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1.6.2 Role of tumor-derived EVs in immune regulation  
The role of EVs in immune regulation has also been intensively studied within last 
decades (Liu et al., 2015; Robbins and Morelli, 2014). Tumor EVs exhibit both anti-
tumor and tumor promoting effects via immune activation or suppression. For 
instance, EVs contain tumor associated antigen (TAA), co-stimulatory molecules or 
MHC molecules that can be delivered to DCs and activated DCs will stimulate the 
cytotoxic immune response of tumor-infiltrating T cells (Wolfers et al., 2001). 
However, most of publications argue that tumor EVs may rather perform 
immunosuppressive functions by triggering the expansion of immune suppressive 
cells. Ovarian carcinoma cells secreted EVs, expressing FasL, which can lead to the 
apoptosis of T lymphocytes and a concomitant loss of TCR ζ-chain in patients (Taylor 
et al., 2003). Besides, EVs from bladder, breast, colorectal and prostate cancer are 
also involved in the inhibition of T cells via adenosine production (Clayton et al., 
2011). Nasopharyngeal carcinoma EVs were also shown to inhibit T-cell proliferation, 
Th1 and Th17 differentiation but induce Treg differentiation via the delivery of miRNA 
(Ye et al., 2014). Tumor EVs can also be internalized by other immune cells. 
Pancreatic cancer-derived EVs can inhibit the expression of regulatory factor X-
associated protein (RFXAP), an important transcription factor for MHC II, through 
miR-212-3p in DCs and induce immune tolerance (Ding et al., 2015). 
1.6.3 Clinical application of EVs 
EVs are present in different kind of biological fluids, including blood, urine, ascites, 
bile, breast milk, synovial, cerebrospinal fluid and so on (Théry et al., 2006). Many 
studies have shown elevated EV concentration or specific markers associated with 
tumor EVs in biological fluids of patients with melanoma, ovarian, pancreatic and 
breast cancer, indicating that EVs may serve as a diagnostic marker (Goedert et al., 
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2014; Hood et al., 2011; Melo et al., 2015; Yu et al., 2015). Besides, EVs from renal 
cell carcinoma were described to incorporate lncRNA, namely lncARSR (lncRNA 
Activated in RCC with Sunitinib Resistance) that are correlated clinically with poor 
sunitinib responses (Qu et al., 2016).  
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2 AIM OF THE PROJECT 
MDSCs are known to be a major obstacle for an effective immunotherapy of many 
cancer types (especially melanoma). The goal of this study was to decipher the role 
of melanoma-derived EVs in the conversion of circulating CD14+ monocytes into 
immunosuppressive myeloid cells, namely M-MDSCs. The effects of EVs from 
melanoma cell lines, HT-144 and SK-MEL-28, were tested on purified CD14+ 
monocytes isolated from periphery blood mononuclear cells of healthy donor. The 
suppressive capability of EV-educated monocytes was investigated by analyzing the 
expression of the immunosuppressive mediator PD-L1 and the ability of inhibiting 
CD8+ T cell proliferation as well as IFN-γ production. Additionally, we investigated the 
underlying mechanisms involved in the induction of PD-L1 expression on monocytes. 
Moreover, the possible ligands carried by tumor EVs leading to the stimulation of PD-
L1 expression on monocytes were analyzed. Finally, we tested if the 
immunosuppressive capacity can be induced on monocytes stimulated by EVs from 
plasma of advanced melanoma patients.  
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3 MATERIAL AND METHODS 
3.1 Material 
3.1.1 Cell lines 
Cell line Source Cell type Mutation Medium 
HT-144 ATCC Melanoma cell line BRAF V600E RPMI 
SK-MEL-28 ATCC Melanoma cell line BRAF V600E RPMI 
 
3.1.2 Cell culture products 
Product Company Catalog No. 
0.4 % Trypan blue solution Sigma Aldrich T8154 
Β-Mercaptoethanol (50 mM) Gibco 31350 
Bovin serum albumin Sigma 7030-50G 
Dimethylsulfoxid (DMSO) Merck 109678 
Dimethylsulphoxide Hybrid Max (DMSO) Sigma Aldrich 472301-100ML 
DPBS (1x) Gibco 14190-094 
Fetal Bovine Serum PAN Biotech GmbH 3702-P260718 
Bicoll Merck L 6715 
HEPES Buffer (1M) Sigma Aldrich H0887 
MACS BSA Stock Solution (10 %) Miltenyi Biotec 130-091-376 
MEM NEAA (100x) Gibco 11140-035 
OptiMEMTM Gibco  31985070 
Penicillin/ Streptomycin PAA P11-010 
RPMI Medium 1640 (1x) + GlutaMAX™ Gibco 61870-010 
sodium pyruvate (100 mM) Gibco 11360-039 
UltraPure™ EDTA (0.5M, pH 8.0) Gibco 15575 
X-Vivo 20 Lonza BE04-448Q 
 
3.1.3 Cell culture media 
Name Composition 
Full RPMI Medium 
500 ml RPMI Medium 1640 (1x) + GlutaMAXTM  
10 % FBS 
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1 % P/S 
Serum free RPMI Medium 
500 ml RPMI Medium 1640 (1x) + GlutaMAXTM 
1 % P/S 
Full Monocyte Medium 
500 ml RPMI Medium 1640 (1x) + GlutaMAXTM 
10 % FBS 
1 % P/S 
10 mM HEPES 
1 mM Sodium Pyruvate 
50 μM β-Mercaptoethanol 
1 mM MEM Non-essential amino acids 
Monocyte EV-depleted 
medium  
500 ml RPMI Medium 1640 (1x) + GlutaMAXTM 
10 % FBS (Ultracentrifuged at 23000 rpm for 16h) 
1 % Penicillin/ Streptomycin 
10 mM HEPES 
1 mM Sodium Pyruvate 
50 μM β-Mercaptoethanol 
1 mM MEM Non-essential amino acids 
 
3.1.4 Kits 
Product Company Catalog No. 
CD14 MicroBeads, human Miltenyi Biotec 130-050-201 
CD8 MicroBeads Miltenyi Biotec 130-045-201 
CellROX® Reagents  Thermo Fisher Scientific C10422 
FoxP3/ Transcription Factor Fixation/ eBioscience 00-5521-00 
Permeabilisation Concentrate and 
Diluent 
    
Human IFN-γ ELISA MAX™ Deluxe Biolegend 430104 
NOS Detection Kit Cell technologies NOS200-2 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific 23227 
Pierce™ LAL Chromogenic Endotoxin 
Quantitation Kit 
Thermo Fisher Scientific 88282 
SensiFAST™ SYBR® Lo-ROX Kit Bioline BIO-94020 
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Toxisensor™ Chromogenic LAL 
Endotoxin Assay 
GeneScript L00350 
Venor ® GeM Classic Mycoplasma 
Detection Kit 
Minerva 11-1050 
 
3.1.5 Antibodies 
      Primary Antibodies 
 
Name Clone Company Catalog No. 
CD9 MZ3 Biolegend 124802 
CD81 5A6 Biolegend 349501 
CD63 H5C6 Biolegend 353013 
Calreticulin D3E6 Cell signaling 12238S 
GAPDH FF26A/F9 Biolegend 649202 
gp100 HMB45 Dako MA5-16712 
ALIX 3A9 Cell signaling 2171S 
Bcl-2 100 Biolegend 648701 
Human Phospho-RelA/NF-κB S536 RnD Systems MAB72261-SP 
Human/Mouse RelA/ NF-κB D14E12 RnD Systems MAB50781 
CD282 (TLR2) 
Antibody,Functional Grade 
6C2 eBioscience™  16-9021-81 
CD284 (TLR4) 
Antibody,Functional Grade 
HTA125 eBioscience™  16-9917-82 
Mouse IgG2a κ Isotype 
Control,Functional Grade 
eBM2a eBioscience™  16-4724-82 
 
     
      Secondary Antibodies 
 
Name Clone Company Catalog No. 
Anti-Mouse IgG Polyclonal Sigma-Aldrich A9044-2ML 
Anti-Rabbit IgG Polyclonal Sigma-Aldrich A0545-1ML 
Anti-Rat Polyclonal Sigma-Aldrich A9037-1ML 
      
       
       Conjugated Antibodies 
   Material and Methods 
 
31 
 
 
Name Fluorochrome Clone Company Catalog No. 
CD14 Percp-Cy5.5 MφP9 BD 562692 
CD11b APC ICRF44  BD 550019 
HLA-DR APC-Cy7 L243  BD 335796 
PD-L1 PE-Cy7 MIH1  BD 558017 
CD8 Pacific Blue RPA-T8 BD 558207 
Annnexin V PE   BD 556421 
3.1.6 Primers for mRNA 
Primer Species Orientation Sequence 
β-actin Human 
forward 5’-GCCCTGAGGCACTCTTCCA-3' 
reverse 5’-CCAGGGCAGTGATCTCCTTCT3' 
IL-1β Human 
forward 5’-TGTAATGAAAGACGGCACACC-3' 
reverse 5’-TCTTCTTTGGGTATTGCTTGG-3' 
IL-6 Human 
forward 5’-GGTACATCCTCGACGGCATCT-3' 
reverse 5’-GTGCCTCTTTGCTGCTTTCAC-3' 
IL-10 Human 
forward 5’-CGATTTAGAAAGAAGCCCAA-3' 
reverse 5’-TCAACAGCTAGAAAGCGTGGT-3' 
TNFα Human 
forward 5’-GCCAGAGGGCTGATTAGAGA-3' 
reverse 5’-CAGCCTCTTCTCCTTCCTGAT-3' 
CCL2 Human 
forward 5’-GACCAGGAAAGAATGTGAAAG-3' 
reverse 5’-GCTCTGCCAATTGACTTTCCTT-3' 
PD-L1 Human 
forward 5’-TATGGTGGTGCCGACTACAA-3' 
reverse 5’-TGGCTCCCAGAATTACCAAG-3' 
Bcl-2 Human 
forward 5’-TTGTGGCCTTCTTTGAGTTCGGTG-3' 
reverse 5’-GGTGCCGGTTCAGGTACTCAGTCA-3' 
Bcl-XL Human 
forward 5’-CTG AATCGGAGATGGAGACC-3' 
reverse 5’-TGGGATGTCAGGTCACTGAA-3' 
Mcl-1 Human 
forward 5’-AGAAAGCTGCATCGAACCAT-3' 
reverse 5’-CCAGCTCCTACTCCAGCAAC-3' 
survivin Human 
forward 5’-CAGATTTGAATCGCGGGACCC-3' 
reverse 5’-CCAAGTCTGGCTCGTTCTCAG-3' 
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Bax Human 
forward 5’-CCTGTGCACCAAGGTGCCGGAACT-3' 
reverse 5’-CCACCCTGGTCTTGGATCCAGCCC-3' 
Caspase3 Human 
forward         5’-TCCTGAGATGGGTTTATGT-3' 
reverse         5’-ATGTTTCCCTGAGGTTTGC-3' 
 
3.1.7 shRNA 
TRC Number Gene Clone ID Company 
TRCN0000001025 HSP90AA1 NM_005348.x-616s1c1 Sigma-Aldrich 
TRCN0000001028 HSP90AA1 NM_005348.x-867s1c1 Sigma-Aldrich 
TRCN0000207114 shControl    Sigma-Aldrich 
 
3.1.8 Chemicals and biological reagents 
Product Company Catalog No. 
10 % Tween® 20 Solution  BioRad  161-0781  
10 x Permeabilization Buffer  eBioscience  00-8333-56  
7-AAD BD 51-68981E 
ACK lysis buffer  Gibco  A10492-01  
Acrylamide solution  Carl Roth  2267.2  
Albumin IgG free  Carl Roth  3737.4  
Amiloride,5’- (N, N-Dimethyl)-
hydrochloride  
Enzo  
ALX-550-261-
M005  
Ammonium persulfate (APS)  Sigma-Aldrich  A-3678  
ATX Ponceau S red staining solution  Sigma-Aldrich  09189-IL-F  
Carboxyfluorescein succinimidyl ester 
(CFSE) 
Biolegend 423801 
Clear PAGE LDS sample buffer (4x)  Invitrogen  MP0007  
Glycine  Carl Roth  3908.1  
Methanol  Carl Roth  8388 
MISSION® shRNA Bacterial stock  Sigma Aldrich  SHCLNG  
MISSION® TRC2 pLKO.5-puro Non-
mammalian Control Plasmid DNA  
Sigma Aldrich  SHC202  
Lipofectamine® RNAiMAX Life Technologies 13778075 
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Transfection Reagent 
Lipofectamine 2000 Life Technologies 11668030 
PageRuler Protein ladder prestained  
Thermo Fisher 
Scientific  
26616 
Pierce® ECL Western Blotting 
Substrate  
Thermo Fisher 
Scientific  
#32106  
Pierce® RIPA Buffer 100 ml  Sigma Aldrich  89900 
Powdered milk  Carl Roth  T145.3  
Roti-Phenol/ 
Chloroform/Isoamylalkohol  
Carl Roth  A156.1  
Rotiphorese Gel 30 (37,5:1)  Carl Roth  3029.1  
SDS  Carl Roth  0183.3  
SIG10 5α Chemically Competent cells  Sigma Aldrich  CMC  
Temed  BioRad  #1610800  
TRIS  Carl Roth  0188.3  
Trizol ® Reagent  Life Technologies  15596018 
Trypan Blue Solution  Sigma Aldrich  T8154  
RBC Lysis Buffer (10x) Biolegend 420301 
Dynabeads® Human T-Activator 
CD3/CD28 
Gibco  111.31D 
Annexin V Binding Buffer (10X) BD 556454 
NF-B Activation Inhibitor VI, BOT-64 Sigma Aldrich  113760-29-5 
 
 
3.1.9 Solutions    
Name Composition 
Freezing medium 1 
60 % FBS 
40 % X-VIVO 20 
Freezing medium 2 
75 % FBS 
25 % DMSO 
1 x TBS  
5 mL 1 M Tris/HCl, pH 8 
15 mL 1 M NaCl 
470 mL ddH2O 
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Stacking polyacrylamide gel  
6 mL ddH2O 
1.35 mL 30 % Acrylamide solution 
2.5 mL 0.5 M Tris/HCl, pH 6.8 
100 μL 10 % SDS 
100 μL 10 % APS 
10 μL TEMED 
10 % Separating polyacrylamide gel  
21.3 mL ddH2O  
13.3 mL 30 % Acrylamide solution  
5.3 mL 3 M Tris/HCL, pH 8.8  
400 μL 10 % SDS  
133 μL 10 % APS  
TEMED 
10 x Running buffer 
30 g Tris base  
144 g Glycine  
10 g SDS  
10 L ddH2O 
10 x Transfer buffer  
121.2 g Tris base 
576 g Glycine 
4 L ddH2O 
Blocking buffer for western blot 
DPBS 
3 % BSA 
0.05 % Tween-20 in TBS 
FACS buffer 
DPBS 
2 % FBS 
0.2 % NaN3 
MACS buffer 
DPBS 
1% BSA 
0.5 mM EDTA 
NP-40 lysis buffer  
50 mM Tris HCl, pH 8.0 
150 mM NaCl 
5 mM EDTA 
10 % NP40 
1 x Protease Inhibitor 
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3.1.10 Routine laboratory material 
Product Company Catalog No. 
6-well flat bottom with lid 
Thermo Fisher 
Scientific 140675 
12-well flat bottom with lid BD 353043 
24-well flat bottom with lid Greiner bio-one 622160 
96-well flat bottom with lid TPP® 92096 
96-well U-bottom with lid Sigma Aldrich M9436-100EA 
serological pipettes: 5, 10 and 25 
mL, sterile Greiner bio-one 606180; 607180 
15 mL conical tubes Falcon 352096 
50 mL conical tubes Falcon 352070 
Amicon® Ultra Centrifugal tube Merck Millipore UFC905024 
Cellstar Cell culture flask 25 cm2  Greiner  658170 
Cell culture flasks T75 Sigma Aldrich C7231-120EA 
TC dish, 150 Standard  Sarstadt  3903 
Cryovial, 2 mL sterile Sigma Aldrich V5760-500EA 
 Filter tips: 20, 200, 1000 μL Steinbrenner L1000 
Freezing Container, "Mr. Frosty"     
Safe lock tubes: 0.5, 1.5 and 2 mL Eppendorf 
SL-GPS-L10, 
L250, 
Filter tips: 20, 200, 1000 μL Steinbrenner L250, L1000 
Syringe 1 mL BD   
Neubauer chamber  Brand    
Needles Sterican®  B. Braun  4657705 
Stericup&Steritop 0.22 μM Millipore 
Express PLUS membrane  Merck Millipore  SCGPU02RE  
LeucoSep tubes  Greiner Bio-one   
iBlot Transfer Stack 
Thermo Fisher 
Scientific  IB24002  
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ThickBlot Filter Paper  BioRad  1703 
PVDF membrane  
Thermo Fisher 
Scientific  88520 
 
 
3.1.11 Laboratory equipment 
 
Device  Name Provider  
Balance BP 3100P Sartorius 
Cell culture incubator Hera cell  Heraeus  
Centrifuges  
BiofugeprimoR  Heraeus  
MEGAFUGE 40R  Heraeus 
Labofuge 400R  Heraeus   
Confocal microscope TCS SP2 Leica 
Flow cytometer FACS Canto II BD Biosciences  
Flow cytometer  FACS Lyric BD Biosciences  
Heating block  Digital Block Heater HX-2  Peqlab  
Imaging system  Fusion SL  VilberLourmat  
Laminar flow hood Hera safe 
Thermo Electron 
Cooperation 
Magnetic stirrer RCT basic IKA Werke 
Microplate Reader Tecan infinite M200 Tecan 
Microscope DMIL Leica 
MACS Magnet and 
stand 
  Miltenyi Biotec 
N2 tank     
Nanoparticle tracking 
system 
NanoSight NS300 Malvern 
Nanodrop 
Spectophotometer 
    
Pipettes  Transferpette ® S  Brand  
Power supply  
PowerPacTM HC High 
Current  
BioRad  
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Real-Time PCR 
machine 
MX3005 qPCR Systrm  Stratagene  
Shaker  Logic shaker  NeoLab  
Thermal Cycler  
DNA Engine Peltier Thermal 
Cycler  
BioRad  
Transfer device  iBlotTM Gel Transfer Device  Thermo Scientific  
Ultracentrifugation rotor Surespin 630 Sorvall 
Ultracentrifuge  SorvallDiscovery 90SE  Hitachi  
Vortexer 
REAX top Heidolph 
Vortex Genie 2 Scientific Industries 
Water bath DC3 HAAKE, GFL 
 
 
3.1.12 Software for data analysis 
Product Version Company 
Flow Jo 7.6.1 Tree Star Inc., Ashland, USA 
GraphPad PRISM 5 GraphPad Software Inc., San Diego, USA 
Image J 1.51d NIH 
Mendeley 1.46 Mendeley 
I control 1.10 1.10 TECAN 
 
  
   Material and Methods 
 
38 
 
3.2 Methods 
3.2.1 Cell culture  
The human melanoma cell lines (HT-144, SK-MEL-28) were cultured in 75 cm2 full 
RPMI media indicated in table 3. All cell lines were cultured in a humidified incubator 
at 37°C and 5 % CO2. Cell lines were sub-cultured every 2-4 days as soon as they 
reached around 70 % confluency. For passaging adherent cells, 3 mL of 1 x Trypsin 
containing 5 mM EDTA was used and added to the cells. Afterwards, the cells were 
incubated for 3 - 5 min at 37 °C to allow the cells to detach. The cells were then 
transferred into pre-warmed medium in Falcon tubes and were centrifuged (1500 
rpm, 7 min, RT). After removal of the supernatant, the cells were resuspended in 20 
ml of the respective cell culture media for culture (37°C, 5% CO2).  
3.2.2 Counting of cells  
When necessary, the respective cell suspension was centrifuged for 7 min at 1500 
rpm and pellets were resuspended in an appropriate volume of cell culture medium. 
Next, 90 µL trypan blue solution was mixed with 10 µL cell suspension for live-dead 
discrimination. Live cells were counted with a Neubauer counting chamber and the 
total cell number was calculated using the following formula: 
Total live cells/mL = Counted cells/counted squares x dilution factor x10x 104 cells/mL 
3.2.3 Isolation of EVs from melanoma cell line 
For EV isolation from conditioned media of human melanoma cell lines, a protocol 
was established based on the previously described method (Lobb et al., 2015). Cells 
were expanded and grown to 70% confluency in 75 cm2 cell culture dishes. The 
media was discarded. The cells were washed with PBS then further incubated for 24 
hours in serum free media. Next, the media were harvested after 24 hours and 
centrifuged at 1500 rpm at 4 ºC for 7 minutes to remove detached cells. Supernatant 
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was collected and frozen at -20 °C until use. On the day of EV isolation, the frozen 
supernatant was thawed at 37°C and then filtered through 0.22 μM filters to remove 
contaminating apoptotic bodies and cell debris. Clarified EV containing media was 
concentrated by a 100 kDa size exclusion filtration at 3800 g for 30 min at RT using 
Amicon Ultra Centrifugal Filters which allowed the separation of protein. The 
concentrated media was collected from the filters, diluted with filtered PBS (0.22 μM 
filters), and then ultra-centrifuged for 90 min at 100.000 g to pellet EVs. The 
supernatant was carefully removed, and the pellet was resuspended in 500 μL sterile 
filtered PBS and stored at -20 °C. The method for EV isolation from melanoma cell 
lines is illustrated schematically in Fig. 6. 
 
 
Figure 6: Isolation of EVs from melanoma cell lines. Cell culture media was sterile filtered 
with 0.22 μM filters followed by ultrafiltration at 3800 g for 30 min. EVs were pelleted by 
ultracentrifugation by 100,000 g at 4°C for 90 min. 
 
3.2.4 Isolation of EVs from plasma of melanoma patients 
3.2.4.1 Plasma preparation 
Whole blood was obtained from melanoma patients in heparin-coated tubes and 
proceeded within 2 hours. Density gradient centrifugation at 400 g for 30 min using 
Biocoll (Biochrom, Berlin, Germany) was used for separation of plasma, peripheral 
blood mononuclear cells (PBMCs) from erythrocytes and others. Isolated PBMCs 
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were adjusted to 107 cells and cryopreserved in RPMI supplemented with 30% 
human serum and 10% DMSO at −80°C. Plasma was aliquoted to clean tubes and 
stored at -80°C until use. 
3.2.4.2 Isolation of EV from plasma of melanoma patients 
For the isolation of EVs from human plasma, 5mL plasma was thawed, diluted with 
PBS and centrifuged at 2000 g for 10 min to remove platelets and cell debris. The 
supernatant was taken and filtered through a 0.22 µM Syringe Filter (Merck). Filtered 
plasma was centrifuged at 10,000 g for 30 min to remove debris and then EVs were 
pelleted by ultracentrifugation at 100,000 g for 70 min. The pellet was re-suspended 
in sterile-filtered PBS and frozen at -20°C until use. In some experiments, EVs were 
depleted from plasma by ultracentrifugation at 100,000 g and used as controls. 
 
 
 
Figure 7: Isolation of EVs from plasma melanoma patients. Whole blood was taken from 
patients and centrifuged at 400 g for 30 min for the collection of plasma and PBMC. Plasma 
was further centrifuged at 2000 g for 10 min after freeze-thaw to get rid of platelets. Cell 
debris, platelets and apoptotic bodies were removed via centrifugation at 2000 g for 10 min 
and at 10,000 g for 30 min. EVs were pelleted via ultracentrifugation at 100,000 g at 4°C for 
90 min. 
 
   Material and Methods 
 
41 
 
3.2.5 Quantification of purified EVs  
3.2.5.1 Nanoparticle tracking analysis (NTA) 
Light scattering technologies, especially nanoparticle tracking analysis is widely used 
to measure the particle numbers and size distribution profiles. Prior to analysis, EVs 
were diluted 1:1000 with sterile PBS and then loaded into Malvern NanoSight NS300 
device. Videos were recorded five times (60 seconds each) with camera level set 
between 7 and 10 and detection threshold set at 5. NTA 3.0 software was used to 
calculate the size and concentration of the particles with corresponding standard 
error via analysis of recorded video. Temperature was monitored and updated after 
each run. After each batch of EV, detection chamber was washed with sterile PBS. 
3.2.5.2 Protein quantification  
To determine the protein concentration of or EVs and cell lysates, Pierce BCA 
Protein Assay Kit (Thermo Scientific) was used according to the manufacturer’s 
instructions. First, working reagent was prepared by mixing 50 parts of BCA reagent 
A with 1 part of BCA reagent B. Then, 10 μL of standards and diluted samples were 
pipetted out on a 96-well plate and 200 μL of WR was added to each well. The plate 
was incubated at 37°C for 30 min followed by the measurement of the absorbance at 
562 nm using the microplate reader. 
3.2.6  Biochemical methods 
3.2.6.1 RNA isolation and cDNA synthesis  
Total RNA was isolated from cells using TRIzol according to the manufactures 
protocol. RNA concentration and quality were measured by TECAN 200 
spectrophotometer. Isolated RNA was stored at -80 °C until further downstream 
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measurement. cDNA was synthesised using the Sensi FAST™ cDNA Synthesis Kit 
from Bioline (Table 1).  
 
Table 1: Program for cDNA synthesis amplification 
 
 
3.2.6.2 RT-PCR 
To determine the expression levels of mRNA, quantitative real-time PCR (qPCR) was 
performed using SYBR Green Master Mix (Applied Biosystems, Life technologies) on 
a Stratagene Mx3005P real-time PCR system. In all experiments, 18s was used as 
the housekeeping gene and the values were normalized to it. Relative gene 
expressions were quantified by calculating (ΔΔCt). Amplification program is shown in 
Table 2. 
 
Table 2: Program for mRNA amplification 
 
3.2.6.3 Protein isolation  
Cells were cultured in 6-well plates for whole cell protein isolation. On the day for 
isolation, cells were detached from the well with a cell scraper on ice and washed 
with PBS at 300 g for 7 min. Pellets were resuspended in 300 μL NP-40 lysis buffer 
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with Protease Inhibitor. In order to maintain the phosphorylation of proteins, 1x of 
phosphorylation inhibitor was added to the lysis buffer. The cells were lysed for 30 
min at 4 °C on a shaking platform and afterwards centrifuged at 13,000 g for 15 
minutes at 4 °C. The supernatant containing the proteins was transferred to a fresh 
Eppendorf tube and stored at -20 °C. To determine the protein concentration, method 
indicated in 3.2.5.2 was used. 
3.2.6.4 Western Blot 
3.2.6.4.1 SDS-polyacrylamide gel electrophoreses (SDS-PAGE) 
In order to analyze the protein expression in whole cell lysates or EVs by Western 
Blot, proteins were separated according to their molecular weight by discontinuous 
SDS polyacrylamide gel electrophoresis (SDS-PAGE). Protein was first mixed with 
LDL-sample buffer supplemented with 5 % β-mercaptoethanol, heated for 5 min at 
95°C and then placed on ice. 30 μg of protein from each sample was loaded on a 10 
% SDS gel and separated at 100 V until the leading front runs out of the SDS gel. For 
determination of the protein size, a protein standard was applied. Electrophoresis for 
CD9-Western Blots was carried out under non-denaturing conditions with β-
mercaptoethanol free loading buffer.   
3.2.6.4.2 Protein transfer  
After electrophoresis, proteins were transferred on to a Polyvinylidenfluorid (PVDF) 
membrane and a semi-dry botting technique was used. Three sheets of waterman 
papers were soaked with 1 x transfer buffer and put onto the anode of the blotting 
device. PVDF membrane was first activated with methanol for 1 minutes, rinse with 
transfer buffer, and then placed on top of the waterman papers. Subsequently, the 
SDS-gel was equilibrated in transfer buffer and placed above the PVDF membrane, 
followed by three sheets of waterman papers. The proteins were then transferred 
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onto the PVDF membrane at 0.6 mA/per blotting stack for 90 min. Afterwards, 
transfer of proteins to the membrane were routinely checked with Ponceau S 
staining.  
3.2.6.4.3 Protein detection   
After transfer, PVDF membrane was blocked for 30 min at room temperature with 3 
% BSA in TBS. In parallel, primary antibodies were prepared in TBS-T supplemented 
with 3 % BSA. The membrane with appropriate dilutions of primary antibody was 
incubated overnight at 4°C on a shaking platform. Afterwards, the membrane was 
washed with TBST for three times, and then incubated with appropriate dilution of 
conjugated secondary antibody at room temperature for 1 h. Before signal 
development, the membrane was washed again with TBS-T for three times. Pierce® 
ECL Western Blotting Substrate was used for protein detection and the images were 
acquired by the Fusion SL detection device. 
3.2.6.5 Magnetic-activated cell sorting (MACS) 
Human CD14+ monocytes and CD8+ T cells were purified from the leukocyte 
concentrates purchased from the German Red Cross Blood Service Baden 
Württemberg-Hessen according to the manufacturer’s protocol (Miltenyi). Briefly, 
after PBMC isolation, an appropriate number of cells was incubated with magnetic 
nanoparticles coated with anti-CD14 or anti-CD8 antibody to allow the attachment of 
cells expressing corresponding antigens to the magnetic nanoparticles. After 
incubation, the cells were positively selected via columns in magnetic field. The 
isolated monocytes and T cells fractions were stained with anti-CD14 or anti-CD8 
antibodies. The purity was > 90%. 
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3.2.6.6 Fluorescence-activated cell sorting (FACS) analysis 
3.2.6.6.1 Surface staining  
1x106 cells from culture or primary cells isolated from the peripheral blood were 
washed and suspended in 100 μL FACS buffer with Fc-blocking reagent for 10 min at 
4 °C. Appropriate fluorochrome-conjugated monoclonal antibodies were added and 
cells were further incubated for 30 min at 4°C in the dark. When biotinylated 
antibodies were used, cells were washed with FACS buffer and incubated with 
conjugated streptavidin for an additional 30 min at 4°C. Afterwards, stained cells 
were washed twice with 200 μL FACS buffer by centrifugation at 1500 rpm for 5 min 
to remove the unbound antibodies and measured with FACS Canto II (BD) using the 
BD Diva Software V.6.1.1.  
3.2.6.6.2 Intracellular staining  
For intracellular staining, cells were first stained for surface markers as described 
above. Afterwards, cells were washed and incubated in 100 μL of Fixation/ 
Permeabilization solution (1:4 dilution) (eBioscience) for 45 min at 4 °C. 
Subsequently, fluorescence-labelled antibodies against intracellular antigens was 
added and washed twice with 200 μL 1x Perm/Wash buffer (ebioscience). Cells were 
incubated for 30 min at 4°C in the dark. Then, cells were washed with 1x Perm/Wash 
buffer, resuspended with 100 μL of FACS buffer and measured by flow cytometry. 
Flow Jo software 7.6.1 was used for data analysis. 
3.2.6.6.3 EV staining 
Since EVs are too small to be detected by BD Canto and BD Lyric flow cytometers, 
latex beads (4 μM) were used to couple with EVs for protein detection indirectly. 
First, latex beads were diluted 1:1000 with PBS and incubated with 50μg EVs from 
each sample for 1 h at room temperature on a shaking platform with the speed of 900 
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rpm. To stop the coupling reaction, 100 μL of 1M Glycin/PBS and 100 μL of 10 % 
BSA in PBS were added followed by the incubation at room temperature for 30 min 
on a shaking platform.  EV-bead complexes were washed twice with 1 mL FACS 
buffer for 2 min at 13.000 g and then subjected to staining with appropriated dilution 
of primary antibody for 1 h at 4 °C in the dark. Afterwards, EV-Bead complexes were 
washed twice and incubated with secondary antibody diluted with FACS buffer for 60 
min at 4°C in the dark followed by two times washing at 13.000 g for 2 min with 1 ml 
FACS buffer. Flow cytometry analysis was performed for detection of respective 
protein. 
3.2.6.7  T cell proliferation assay 
The proliferation rate of CD8+ T cells was checked to evaluate the 
immunosuppressive activity of melanoma-EV educated monocytes. First, CD14+ 
monocytes were isolated as described in 3.2.7 and stimulated with melanoma EVs 
for 16h. Next day, EVs were washed out twice at 1500 rpm for 5 min at 4 °C. Freshly 
isolated CD8+ T cells were stained with 5  Carboxyfluorescein diacetate 
succinimidyl ester (CFSE) and added to the plate with or without activation with pre-
washed CD3/CD28 Dynabeads. After 72 h incubation, the supernatants were 
collected for IFN-γ detection, and cells were washed at 1500 rpm for 5 min. Fc-Block 
reagent and anti-CD8 antibody were added for 20 min at 4 °C in the dark. Flow 
cytometry analysis was performed after washing and re-suspended in 100 μL FACS 
buffer. 
3.2.6.8  Enzyme-linked immunosorbent assay (ELISA) 
For detection of IFN-γ secretion by CD8+ T cells after co-culture with melanoma EV 
stimulated monocytes, cell supernatant of human CD8+ T cells was harvested and 
measured according to manufacturer’s instructions (Biolegend). Briefly, 96-well plate 
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was coated with Human IFN-γ capture antibody overnight at 4°C followed by 4 times 
washing of the plate. Non-specific binding was blocked by incubating with assay 
diluent at RT for 1 hour on a plate shaker. After 4 times washing, pre-diluted (1:10) 
samples and standards was added and incubated at RT for 2 hours with shaking. 
Afterwards, the plate was incubated with 100 of diluted detection antibody at RT for 1 
hour followed by incubation with 100 μL of diluted Avidin-HRP solution at RT for 30 
minutes. The plate was washed 4 times in between and 5 times afterwards. 100 μL of 
freshly mixed TMB substrate solution was added and incubated in the dark for 20 
minutes. The reaction was stopped with 100 μL of stop solution and the absorbance 
was acquired at 450 nm within 15 min.  
3.2.6.9  Transwell migration assay 
Cell migration towards a gradient of EV containing serum-free monocyte culture 
medium was performed in a transwell assay. Briefly, CD14+ monocytes were isolated 
as indicated in 3.2.7 and re-suspended in serum-free monocyte culture media at the 
concentration of 2.5x105/mL. 750 μL serum-free monocyte culture medium with EVs 
of different concentration was added in a 24-well plate. Afterwards, the trans-wells 
were inserted in 24-well plate and 200 μL cell suspension was added into each trans-
well and incubated at 37 °C for 3 h. Subsequently the medium was removed from 
each insert and all inserts were wash twice with PBS. The cells on the trans-wells are 
fixed by formaldehyde (3.7% in PBS) at RT for 2 min followed by two times wash by 
PBS. 100% methanol was used to permeabilize cells at RT for 20 min. After the 
permeabilization, the cells were wash twice by PBS and further stained with Giemsa 
at RT for 15 min in the dark. The transwells were washed again for two times and the 
non-migrated cells were scraped off with cotton swabs from the top of the inserts. 
Light microscope was used for counting of the migrated cells. 
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                                    Figure 8: In vitro transmigration assay. 
 
 
 
3.2.6.10 Transduction with lentiviral particles 
Lentiviral transduction was performed by Qian Sun (DKFZ). Briefly, HEK293T cells 
were used for lentiviral particle production. Two independents lentiviral shHSP90AA1 
constructs (shHSP90AA1-1 TRCN0000001025; shHSP90AA1-2 TRCN0000001028) 
and a control vector (shControl TRCN0000207114) were purchased from Sigma-
Aldrich. For transfection, plasmid containing respective shRNA (11 μg) was 
incubated with the packaging plasmids VSV-G (5.5 μg) and pCMV-dR 8.91 (8.25 μg) 
in DMEM and X-treme GENE® (Roche) solution for 30 min. After incubation, they 
were added to HEK293T producer cells. Supernatant of infected HEK293T cells was 
discarded after 12h transfection, and then harvested at 24, 36 and 48h. Supernatants 
were pooled together and filtered with sterile syringe filters (0.22 μM). 0.5 mL of 
filtered supernatant were added to a 6-well plate with seeded human melanoma cells 
(2x105 cells) and incubated with virus for 24 h. Afterwards, human melanoma cells 
were re-infected with the same virus in fresh medium. After 48 h of transduction, the 
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cells were washed twice with PBS and cultured for 72 h followed by a selection of the 
transduced cells with 2 μg/ml puromycin.  
3.2.6.11 Patients 
In this study, 30 patients with melanoma of stages III–IV (AJCC 2018) who were 
seen at the Skin Cancer Center (University Medical Center Mannheim, Germany) 
from 2013 to 2018 (ethics approval: 2010‐318MMA) were included valu. Briefly, 
heparinized blood samples were subjected to the density gradient centrifugation 
using Biocoll (Biochrom). After removal of plasma, PBMC was collected, aliquoted 
and stored at -80 °C. For each patient, PBMCs before and post treatment until the 6th 
treatment cycle was collected and separated into responding and non-responding 
groups. Patients with complete response (CR) and partial response on ICI therapies 
were classified as responders, whereas those with stable disease (SD) and 
progressive disease (PD) were considered as non-responders (Fig. 9).  
 
 
Figure 9: Scheme of study design 
 
 plasma  
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3.2.7 Statistical analysis 
Statistical analyses were performed using GraphPad Prism software. Results were 
assessed with one-way ANOVA or an unpaired two-tailed Student’s t test. Survival 
curves were generated using the product limit (Kaplan-Meier) method, and 
comparisons were conducted using the log-rank (Mantel-Cox) test. A p value below 
0.05 was considered statistically significant. 
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4 RESULTS 
4.1 Characterization of EVs 
4.1.1 Characterization of EV from melanoma cell lines 
An updated guideline “Minimal information for studies of extracellular vesicles 2018 
(MISEV2018)” was published in 2018 by the International Society for Extracellular 
Vesicles (Théry et al., 2018). We performed the steps in accordance with this 
guideline to quantify and characterize the protein content in our EV preparations. 
The concentration and size distribution of purified EVs were measured using 
nanoparticle tracking analysis (NTA) that uses the properties of Brownian motion and 
light scattering. A representative histogram of NTA revealed that the particles have 
the mean size at 118 nm and concentration of 1.5 x 1012±3.23x1011 EVs/mL (Fig. 
10A). Isolated EVs were also characterized by Western Blot analysis (Fig. 10B). HT-
144 EVs are tested for the EV-associated markers such as CD9, CD81 and ALIX, 
which are involved in the biogenesis of multivesicular bodies (El Andaloussi et al., 
2013). Those EVs were negative for the endoplasmic reticulum resident protein 
calreticulin, confirming that the EV preparations were not contaminated with cellular 
components (Fig. 11B). Importantly, we also detected the presence of the 
melanoma-associated antigen gp100 on HT-144 EV that was also detected on HT-
144 cells (Fig. 10C). We coupled HT-144 EV with latex-beads and measured the 
coupled EVs by flow cytometry. The gating strategy is shown in Fig. 11. In parallel, 
the expression of gp100 on HT-144 EV was also confirmed by Western Blot 
(Fig.10D). 
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Figure 10: Characteristic of HT-144 EV. A) Representative Nanoparticle Tracking Analysis 
(NTA) for the size determination of HT-144-EV. B) Western blot analysis of EVs markers 
(CD9, CD81 and ALIX), loading control (GAPDH) and negative control (calreticulin) in EVs. 
C) HT144-EV were coupled with latex beads and stained for gp100. The expression level of 
gp100 was measured via flow cytometry. Solid line without shading indicates the secondary 
antibody control and Solid line shows the expression of gp100.  
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Figure 11: Representative dot plot showing the gating strategy of latex bead-
conjugated EVs. Latex beads were gated according to SSC-A and FSC-A in A) and 
the fluorescence detection of isotype (grey) or CD9 (red) on HT-144 EV shows in 
B). 
 
4.1.2 Characterization of EV from plasma of melanoma patients 
It was described that platelet-derived EV may account for over 50% of EVs in serum 
(Gemelli et al., 1993). This makes plasma a better source of EVs (Bemis et al., 
2013).  Based on this, we isolated EVs from plasma of stage IV melanoma patients 
by differential ultracentrifugation. NTA and Western Blots were also made for the 
characterization for plasma-EV of melanoma patients (Fig. 12 A and B). 
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Figure 12: Characteristic of EVs isolated from plasma of melanoma patients. A) 
Representative Nanoparticle Tracking Analysis (NTA) for the size distribution of EVs from 
melanoma patients. B) Western blot analysis shows the expression of EV markers (CD9, 
CD63). 
 
 
4.2 Effect of HT-144 EV on CD14+ monocytes 
As mentioned previously, the expansion and activation of MDSC is strongly 
associated with inflammatory and immunosuppressive factors produced in the tumor 
microenvironment by tumor cells and stroma cells. We selected a panel of cytokines 
such as interleukin (IL)-1β, IL-6, IL-10, and TNF-α as well as chemokine like 
monocyte chemoattractant protein-1 (MCP-1/CCL2). The gene expression of those 
cytokines and chemokines was measured in monocytes by RT-PCR. We observed a 
pronounced upregulation of cytokine and chemokine transcription in monocytes 
following 16 h exposure to HT-144 EV (Fig. 13 A).  
Since CCL-2 was shown to play an important role in the attraction of M-MDSC in the 
tumor microenvironment (Chang et al., 2016), we examined whether the incubation 
with HT-144 EV affected the migration of monocytes via Boyden chamber assays. 
We could see that monocyte migration ability was significantly stimulated by 
melanoma derived EVs in a dose dependent manner. (Fig. 13B, C) 
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Figure 13: HT-144 EVs induce cytokine gene expression and migration activity of 
monocytes. A) Expression of cytokines and chemokines in monocytes was measured by 
RT-PCR normalized to β-actin. B) Monocytes in the transwell migration assay were 
incubated with HT-144 EVs at the concentration of 1 µg/mL, 5 µg/mL and 10 µg/mL. The 
migrated cells were stained with Gemsa solution after 3 h and counted manually under 
microscope. Five representative field in each well were quantified to determine the number of 
migrated cells (mean ± SEM; n=3) and representative photos are shown in C.* p＜0.05，** p
＜0.01，*** p＜0.001. 
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4.3 HT-144 EVs protect CD14+ monocytes from spontaneous apoptosis 
Previous publications showed that EVs from different cells have different effects on 
the survival of their target cells (Andreola et al., 2002; Valenti et al., 2006). To this 
regard, normal human monocytes were evaluated in apoptotic assay following the 
treatment with HT-144 EV. CD14+ monocytes were cultured with or without 15 μg/ml 
of EVs in 24-well plates (2×105 cells/well) in monocyte culture medium. In agreement 
with previously published finding (Valenti et al., 2006), co-culture with EVs resulted in 
a decrease in total apoptosis of monocytes (Fig. 14A and B). Besides, we studied the 
expression of various pro- and anti-apoptotic gene. and found that the expression of 
anti-apoptotic proteins Bcl-2 and survivin were significantly upregulated at the mRNA 
level. Finally, the upregulation of Bcl-2 at the protein level in monocytes was also 
confirmed by Western Blot upon the treatment with HT-144 EV in a time- and dose-
dependent manner (Fig. 14D and E). These observations demonstrated the capacity 
of melanoma EVs to protect monocytes from spontaneous apoptosis via the 
induction of Bcl-2. 
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Figure 14: Effect of HT-144 EV on the apoptosis of primary monocytes. A) 
Representative dot-plots illustrating the apoptotic status of monocytes with or without EV 
stimulation. B) The percentage of apoptotic monocytes compared to the control group. C) 
The expression levels of anti-apoptotic genes Bcl-2, Bcl-XL, Mcl-1 and survivin as well as 
pro-apoptotic genes Bax and Caspase3 in monocytes with or without HT-144 EV stimulation. 
D) Western Blot for Bcl-2 in monocytes upon 10 µg HT-144 EV treatment at 0h, 3h and 24h 
or stimulated with different concentration of HT-144 EV for 24h E). GAPDH was used as a 
loading control. * p＜0.05，** p＜0.01，*** p＜0.001. 
 
 
  Results 
 
58 
 
4.4 CD14+ monocytes show immunosuppressive activity upon HT-144 EV 
treatment 
To determine the immunomodulatory effect of HT-144 EVs on circulating monocytes, 
2 x 105 cells resuspended in 200 μl of medium were pre-incubated with 15 μg HT-144 
EV in 96-well plate for 16 h followed by co-culture with T cells for 72 h. Proliferated 
CD8+ T cells were gated according to the cells without activation by CD3/CD28 
Dynabeads. Gating strategy was shown in Fig. 15. CD8+ T cell co-cultured with 
monocytes without EV stimulation were used as  positive control. 
 
 
Figure 15: Gating strategy of T cell proliferation assay. Live lymphocytes were gated 
using the forward and side scatter characteristics to include both resting and dividing 
cells(left). CD8+ T cells were then gated from the lymphocyte gate (middle). The proliferated 
cells were gated according to the negative control of non-activated T cells A) and CFSE 
staining in activated CD8+ T cells showed the different generation of cells B).  
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We found that monocytes treated with HT-144 EVs significantly impaired CD8+ T 
cells proliferation (Fig. 16A and B) in a manner dependent on EV concentration. The 
inhibitory effect was also dependent on the ration between EV-treated monocytes 
and stimulated T cells.  In parallel, the secretion of IFN-γ in the supernatant of 
proliferating CD8+ T cells were tested. The production of IFN-γ was also decreased 
upon the incubation of T cells with EV-treated monocytes (Fig. 16C).  
 
 
Figure 16: HT-144 EV treated monocytes inhibit CD8+ T cell proliferation and modulate 
IFN-γ production. A) Representative CFSE histograms showing the proliferation of CD8+ T 
cells alone(left), or co-cultured with monocytes (Monocytes: T cells ratio =1:1) stimulated 
without(middle) or with 0.1 µg HT-144 EV (right). B) Inhibition of CD8+ T cell proliferation by 
EV-treated monocytes at indicated Monocytes: T cells ratio. C) IFN-γ secretion by CD8+ T 
cell were tested by ELISA (Monocytes: T cells ratio =1:1). * p＜0.05，** p＜0.01，*** p＜
0.001. 
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4.5 HT-144 EVs upregulate PD-L1 on CD14+ monocytes 
PD-L1 expression on MDSCs has been demonstrated to play a crucial role in 
mediating the immunosuppressive function on cytotoxic T cells. We thus wanted to 
know whether the observed mechanism of EV-mediated suppression of T cell 
activation involved PD-L1. First, we examined the expression of PD-L1 on CD14+ 
monocytes upon the treatment of HT-144 EV by flow cytometry. Compared to the 
cells treated with PBS, we observed a dramatic increase in the frequency of PD-L1+ 
monocytes and the level of PD-L1 expression measured by median fluorescence 
intensity (MFI) (Fig. 17 A, B and C). Furthermore, the application of EVs isolated from 
another melanoma cell line SK-MEL-28 revealed that the same amount of EVs (15 
µg) induced a strong upregulation (Fig. 17 A-C). 
To address the question whether new synthesis of PD-L1 is induced by melanoma 
EVs, we studied PD-L1 expression at the mRNA level. We observed more than two 
times higher PD-L1 mRNA expression in HT-144 EV-treated monocytes compared to 
cells treated with PBS (Fig. 17 D). In the SK-MEL-28 EV treated samples, the 
induction of PD-L1 mRNA was observed, although to a lower extent (Fig. 17 D). 
To further characterize the phenotype of these immunosuppressive monocytes, we 
checked the expression of HLA-DR which is important to distinguish MDSCs from 
monocytes. We found that 6h after the addition of HT-144 EVs, monocytes showed 
an upregulation of HLA-DR. However, upon a longer time exposure to tumor EVs, the 
frequency of HLA-DR+ monocytes and the intensity of HLA-DR expression 
(measured as MFI) was decreased as compared to the monocytes treated with PBS 
(Fig17. E and F). Taken together, the upregulation of PD-L1 and down regulation of 
HLA-DR indicated the conversion of monocytes to MDSCs. 
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Figure 17: PD-L1 expression on monocytes upon the treatment of melanoma EV. 
CD14+ monocytes isolated from buffy coats of healthy donors were treated with EVs of 
melanoma cell lines HT-144 and SK-MEL-28 for 16 h. A) Representative dot plots of PD-L1 
expression on monocytes with or without HT-144 EV treatment after 16 h incubation 
(including isotype control and unstimulated monocytes). B) The level of PD-L1 expression 
measured as frequency of PD-L1+ cells and C) median fluorescence intensity (MFI) of PD-L1 
on CD14+ monocytes. D) The relative PD-L1 mRNA expression levels (normalized to β-actin) 
after the stimulation of HT-144 EVs and SK-MEL-28 EVs for 16 h in CD14+ monocytes were 
measured by RT-PCR. The level of HLA-DR was measured at different time point (n=2) as 
frequency (E) and MFI on CD14+ monocytes (F). * p＜0.05，** p＜0.01，*** p＜0.001. 
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4.6 The involvement of NF-B activation in PD-L1 upregulation 
As mentioned in the introduction, NF-B is a crucial player in regulating the 
expression of pro-inflammatory genes and play an important role in the anti-apoptotic 
effect (Lawrence, 2009; Sen and Baltimore, 2013). Therefore, we wanted to study 
whether tumor-derived EVs could trigger NF-B activation. As shown in Figure 15A, 
NF-B phosphorylation was induced by HT-144 EV in purified CD14+ monocytes. In 
order to further characterize the role of NF-B in the upregulation of PD-L1, a NF-
B Activation Inhibitor VI (BOT-64) was added to monocytes prior to the treatment 
with HT-144 EVs. We observed that the upregulation of PD-L1 on monocytes was 
strongly abrogated with the application of BOT-64 measured by flow cytometry (Fig. 
18B) 
 
Figure 18: HT-144 EV induces NF-B activation in CD14+ monocytes. Western blot 
analysis was performed to assess NF-B activation after 0.5, 1, 1.5 and 3 h stimulation with 
15 µg/mL HT-144 EV. Total NF-B were used as a loading control (A). Flow cytometry was 
performed to measure the PD-L1 expression on HT-144 EV treated monocytes with or 
without prior application of NF-B activation inhibitor BOT-64 (B). * p＜0.05，** p＜0.01，*** 
p＜0.001. 
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4.7 The upregulation of PD-L1 via TLR signaling    
We then sought to determine the mechanisms triggering NF-B activation. Since EVs 
can interact with target cells through a ligand-receptor interaction and TLRs have been 
proposed as potential receptors for EVs (Fabbri et al., 2013; Paschon et al., 2016; Seo et al., 
2016), we decided to test PD-L1 expression using HT-144 EVs as well as TLR2 agonists 
Pam3/CSK4 and TLR4 agonists LPS. Interestingly, PD-L1 expression was strongly induced 
by HT-144 EV, Pam3/CSK4 and LPS (Fig. 19A). Importantly, the effect of tumor derived EVs 
on monocytes for PD-L1 upregulation was at the similar level as TLR2 and TLR4 agonists. In 
addition, we examined the PD-L1 expression on HT-144 EV stimulated monocytes in the 
presence of anti-TLR2, anti-TLR4 blocking antibodies or isotype control antibodies. As 
shown in Fig. 19B, the treatment with anti-TLR4 blocking antibodies completely abrogated 
the induction of PD-L1 expression by HT-144 EVs, whereas anti-TLR2 antibodies could 
inhibit such induction only partially.  
 
 
Figure 19: Involvement of TLR in the upregulation of PD-L1 on CD14+ monocytes. A) 
Monocytes were treated with HT-144 EV, TLR2 agonists Pam3/CSK4 and TLR4 agonists 
LPS for 16 h. PD-L1 expression was detected by flow cytometry. B) Specific blocking anti- 
TLR2, anti-TLR4 or IgG2a κ isotype control was added 1 h prior to the addition of HT-144 
EV. Frequency of CD14+PD-L1+ cells was measured by flow cytometry. * p＜0.05，** p＜
0.01，*** p＜0.001. 
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4.8 Melanoma cells release EVs carrying HSP86 
HSPs are known as TLR ligands for many years, and are abundantly detected in EVs 
derived from different cell types (Reddy et al., 2018; Shi et al., 2018; Zhang et al., 
2017). Based on this, we decided to check the expression and the possible role of 
HSP86 (HSP90) in our EV preparations. As shown in Fig. 20A, both HT-144 and 
HT-144 EV strongly expressed HSP86. However, SK-MEL-28 melanoma cells 
expressed lower level of HSP86 compared to HT-144 cells, and the expression of 
HSP86 was barely detected on SK-MEL-28 EVs by Western Blot. The expression of 
HSP86 on EVs of HT-144 and SK-MEL-28 was also confirmed by flow cytometry by 
coupling of EVs to latex beads. In addition, both melanoma cell lines and EVs 
derived from them displayed a very low expression of PD-L1 (Fig. 20B). Interestingly, 
as shown previously in the chapter 4.5, we observed a higher potential of HT-144 
EVs to upregulate PD-L1 expression on monocytes than that of SK-MEL-28 EVs, 
suggesting the importance of the level of HSP86 expression for the upregulation of 
PD-L1. 
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Figure 20: Expression of HSP86 and PD-L1 on EVs from melanoma cell lines.  A) 
Western Blot analysis was performed to measure the expression of HSP86 and PD-L1 on 
HT-144 and SK-MEL-28 melanoma cell lines as well as on EVs derived from these lines. 
GAPDH and Alix were used as controls for cells and EVs respectively. B) Flow cytometry 
was performed to measure the HSP86 expression on HT-144 EV (red) and SK-MEL-28 EV 
(blue). Grey line indicates the staining with the secondary antibody only (control). * p＜0.05，
** p＜0.01，*** p＜0.001. 
 
4.9 HSP86 knockdown results in the impairment of PD-L1 upregulation 
To further analyze the impact of HSP86+ melanoma EVs on monocytes and its 
immunosuppressive activity, a stable knockdown of HSP86 via shRNA targeting 
HSP90AA1 was used. Two clones were tested, showing HSP86 depletion in HT-144 
cells (Fig. 21A). Clone 1 was chosen for the isolation of EVs (shHSP86 HT-144 EV). 
Expression of HSP86 on EVs isolated from both HT-144 cells transfected with control 
A
B
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shRNA (shSCR HT-144 cells) and shHSP HT-144 cells were measured. A decreased 
expression of HSP86 on shHSP86 HT-144 EV was observed which indicated the 
successful knockdown of HSP86 on tumor cells (Fig. 21B). Then, we examined the 
upregulation of PD-L1 on monocytes treated with shHSP86 HT-144 EV or shSCR 
HT-144 EV. As expected, the knockdown of HSP86 resulted in a decreased ability of 
EVs to upregulate the frequency of PD-L1+ monocytes and the intensity of PD-L1 
expression (Fig. 21A and B). 
 
 
Figure 21: HSP86 is required for PD-L1 upregulation. A) HSP86 expression was 
measured in HT-144 cells transfected with HSP86 shRNA (shHSP86 HT-144) or control 
shRNA (shSCR HT-144) by Western Blot. B) Flow cytometry was used to validate the 
expression of HSP86 in shHSP86 HT-144 EV and shSCR HT-144 EV. Secondary antibody 
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was used as a control. PD-L1 expression was measured in CD14+ monocytes upon the 
treatment with shHSP86 HT-144 EV, shSCR HT-144 or PBS. PD-L1 expression was shown 
as the percentage of CD14+PD-L1+ monocytes among total CD14+ monocytes (C) and as the 
level of PD-1 expression by MFI (D). * p＜0.05，** p＜0.01，*** p＜0.001. 
 
4.10 Functional inhibition of CD8+ T cells by HSP86+ melanoma EVs 
To evaluate whether the immunosuppressive activity of monocytes stimulated by 
melanoma EVs was mainly dependent on HSP86, T cell proliferation assay was 
performed. 2 x 105 CD14+ monocytes were pre-incubated with 15μg shHSP86 HT-
144 EV or shSCR HT-144 EV in 96-well plate for 16 h. After washing out EVs, 
monocytes were incubated with activated T cells.  We observed a significant 
impairment of CD8+ T cells proliferation upon the treatment of monocytes with 
shSCR HT-144 EV. However, the inhibitory effect was abrogated when the shHSP86 
HT-144 EV was applied (Fig. 22A and B). Moreover, decreased production of IFN-γ 
was detected in CD8+T cells cocultured with shSCR HT-144 EV treated monocytes, 
whereas this decrease was not shown in CD8+T cells cocultured with monocytes 
treated with EVs expressing no HSP86 (Fig. 22C).  
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Figure 22: HSP86 on HT-144 EV play a crucial role in acquiring the 
immunosuppressive activity by monocytes. A) Representative CFSE histograms showing 
the proliferation of CD8+ T cells alone (left), CD8+ T cells cocultured with non-treated CD14+ 
monocytes or monocytes treated with shSCR HT-144 EV and shHSP86 HT-144 EV 
respectively. B) Inhibition of CD8+ T cell proliferation by EV-treated monocytes at indicated 
monocytes: T cells ratio. C) IFN-γ secretion by CD8+ T cells was tested by ELISA 
(monocytes: T cells ratio =1:1). * p＜0.05，** p＜0.01，*** p＜0.001. 
 
 
4.11 Circulating EVs from melanoma patients upregulate PD-L1 and show anti-
apoptotic effect on monocytes 
To address the question whether EVs circulating in melanoma patients could induce 
the same effect on normal CD14+ monocytes as EVs isolated from melanoma cells 
lines, we purified the EVs from plasma of stage IV melanoma patients. Apoptotic 
assay and PD-L1 expression on monocytes were tested after their coculture with 
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EVs. We found a strong inhibition of monocyte apoptosis upon the treatment with 
plasma EVs from stage IV melanoma patients as compared to EV-depleted plasma 
(containing only soluble factors) or PBS treated monocytes (control). In addition, we 
observed an increase in the frequency of PD-L1+ monocytes upon the treatment with 
plasma EVs as compared to these values in monocytes incubated with EV-depleted 
plasma or with PBS (Fig. 23B). The level of PD-L1 expression under these conditions 
was also significantly elevated (Fig. 23C).  
 
 
Figure 23: Effects of EV from plasma of melanoma patients on normal monocytes. 
CD14+ monocytes were incubated with EV from plasma of untreated stage IV melanoma 
patients or with plasma of these patients without EV. 7AAD and Annexin V were used for 
staining of apoptotic cells (A). PD-L1 protein expression was presented as the percentage of 
PD-L1+CD14+ cells within total monocytes (B) and as the MFI of PD-L1 (mean ± SEM; n=6) 
(C). * p＜0.05，** p＜0.01，*** p＜0.001. 
 
 
4.12 HSP86 expression and monocyte modulation by EVs from melanoma 
patients undergoing anti-PD-1 therapy  
EVs or their content (proteins or miRNAs) in circulation of patients have been found 
to show promising value for the prediction of clinical response to various therapies of 
melanoma (Fattore et al., 2015; Huber et al., 2018; Tucci et al., 2018). Here we 
investigated the content of HSP in EVs from melanoma patients that responded 
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differently to anti-PD-1 therapy. The level of HSP86 on circulating EVs in non-
responders was much higher than that on EVs from responders (Fig.24 A). However, 
HSP70, which was previously reported to be widely expressed on EVs under various 
pathological conditions, showed very low expression and no difference in responders 
and non-responders (Fig. 24A). Moreover, the immunosuppressive capacity of 
monocytes stimulated by those EVs was tested. A stronger inhibition of CD8+ T cell 
proliferation was observed for monocytes treated with EVs isolated from non-
responders as compared to those treated with EVs from responder or with PBS (Fig. 
24B). Of note, responder EV-treated monocytes showed no, or only marginal 
difference as compared to PBS treated control (Fig. 24B).  
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Figure 24: HSP86 expression on EVs and their capacity to stimulate 
immunosuppressive activity on monocytes.  EVs were isolated from responders (n=3) 
and non-responders (n=2) of melanoma patients undergoing anti-PD-1 therapy. HSP86 
expression was tested in those EVs by flow cytometry and representative histograms were 
shown in (A). Secondary antibody was used as a control. B) CD14+ monocytes were 
incubated with EV from responders and non-responders or with PBS. Inhibition of CD8+ T 
cell proliferation by EV-treated monocytes at indicated monocytes: T cells ratio. 
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4.13 Effects of EVs from melanoma patients undergoing anti-PD-1 therapy  
Based on our previous findings, HT-144 EVs with higher HSP86 expressions had a 
higher capacity of PD-L1 upregulation. Here, we tested whether EVs from 
responders and non-responders that differently expressed HSP86 could induce 
different PD-L1 upregulation on monocytes. Moreover, another marker HLA-DR was 
also checked in parallel to prove the conversion of monocytes into MDSC-like cells. 
As expected, EVs from non-responders can dramatically upregulate PD-L1 and 
showed 20-30% inhibition of HLA-DR on monocytes after 16 h incubation, whereas 
those from responder failed to induce such changes in the expression of PD-L1 and 
HLA-DR. 
 
Figure 25: PD-L1 and HLA-DR expression on monocytes upon the treatment of 
responder and non-responder EVs. CD14+ monocytes isolated from buffy coats of healthy 
donors were treated with EVs from responders (n=3) and non-responders (n=2) for 16 h. A) 
The level of PD-L1 expression measured as the frequency of PD-L1+ cells (left) and MFI of 
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PD-L1 on CD14+ monocytes (right). B) The level of HLA-DR was measured at the same time 
point as the frequency (left) and MFI (right). * p＜0.05，** p＜0.01，*** p＜0.001. 
 
4.14 PD-L1 expression on circulating monocytes predicts the response to anti-
PD-1 immunotherapy 
Next, we used cryopreserved PBMCs isolated from the peripheral blood of 30 
patients with metastatic melanoma before and during therapy to check the 
association of PD-L1 expression on classical CD14+ monocytes with responsiveness 
to anti-PD-1 immunotherapy.  
4.14.1 Clinical characteristics of melanoma patients 
The patients’ mean age was 66.53 years, and 63.3% were female. 22 patients 
(73.33%) were treated with pembrolizumab and 8 patients (26.67%) with Nivolumab 
or Ipilimumab (Table 3). More than half of the patients had lymph node (80.0%) and 
lung (53.33%) metastasis. 10% were classified as stage III by the American Joint 
Committee on Cancer (AJCC) staging system and 90% were AJCC IV. None of the 
patients had received immune checkpoint inhibition immunotherapy before. Table 4 
provides information on the clinical responses. Patients showing complete (3.03%) 
and partial responses (24.24%) were defined as responders, whereas those with 
stable (9.09%) and progressive disease (54.55%) were defined as non-responders. 
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4.14.2  PD-L1 expression on circulating monocytes is associated with anti-PD-1 
response 
Classical monocyte markers CD14, CD11b, HLA-DR were used to define monocytes 
by flow cytometry (Fig 26). 
 
 
Figure 26: Gating strategy of PD-L1 on classical monocytes.  Cell gated for live singlets 
using FSC-A and -H, live singlets gated for lymphocytes using FSC and SSC. Classical 
monocytes were further gated as CD11b+, HLA-DR+ and CD14+. PD-L1 expression was 
gated according to FMO control. 
 
 
In responders, the frequency of PD-L1+ classical monocytes were significantly 
decreased after the first injection of anti-PD-1 antibodies as compared to the basal 
level. In contrast, the percentage of these cells in non-responders showed no 
changes (Fig. 27A). Of note, the frequency of PD-L1+ monocytes after the first 
injection in non-responders was significantly higher than in responders. However, we 
did not observe any difference before the start of the therapy (Fig. 27A). Interestingly 
the intensity of PD-L1 expression measured as MFI displayed no differences (Fig. 
27B). Moreover, to assess the influence of the frequency of PD-L1+ classical 
monocytes after the first injection of anti-PD-1 antibodies on the survival, we 
calculated the optimal cutoff point (17.495%), which discriminated between high and 
low PD-L1 expression. It was found that patients with low frequency of these 
monocytes showed significantly better overall as well as progression free survival 
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(Fig. 27 C and D), indicating a role of this marker in predicting response to such 
therapy.  
 
 
 
 
 
Figure 27: PD-L1 expression on classical monocytes from patients treated with anti-
PD-1 antibodies and its effect on their overall and progression-free survival.  PBMCs 
obtained from the peripheral blood of 30 melanoma patients (point 0 - prior the treatment; 
point 1 - after the first infusion of anti-PD1 antibodies; point 2 - after the second infusion) 
were assessed by flow cytometry. The frequency of PD-L1+ classical monocytes (A) and MFI 
of PD-L1 (B) in patients responding or not responding to the treatment Cs. Overall (C) and 
progression-free (D) survival of melanoma patients displaying high or low expression of PD-
L1 on monocytes after the first infusion of anti-PD-1 antibodies. * p＜0.05，** p＜0.01，*** p
＜0.001. 
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5 DISCUSSION 
EVs secreted by tumor cells are emerging as critical mediators in tumor progression 
and metastasis. They are shown to express oncogenic molecules and to interact with 
cancer cells (Al-Nedawi et al., 2008; Keller et al., 2009). Moreover, they were found 
to modulate the immune system and promote the formation of immunosuppressive 
microenvironment via the interaction with myeloid cells and lymphocytes (Clayton et 
al., 2008; Gross et al., 2012; Peinado et al., 2012; Wilcox and Hirshkowitz, 2009). 
Malignant melanoma is known as a highly immunogenic tumor, and the 
unsatisfactory results of the immunotherapeutic strategies are often due to the 
enrichment of immunosuppressive regulatory leukocytes, especially of MDSCs 
(Holmgaard et al., 2015; Mandruzzato et al., 2009; Meyer et al., 2011, 2014; Nelson 
and Guyer, 2013; Umansky et al., 2014). PD-L1 expression on MDSCs has been 
characterized to be an important mediator of their immunosuppressive activity to T 
cells (Noman et al., 2014; Youn Je-In, Nagaraj Srinivas, Collazo Michelle, 2009). To 
date, the underlying molecular mechanism of the link between tumor-derived EVs 
and PD-L1 upregulation on M-MDSC remains poorly understood.  
5.1 EVs from melanoma cell lines and plasma of patients show typical EV 
characterization 
Various techniques have been used for EV isolation, for example differential (ultra) 
centrifugation, density gradients, polymer-based precipitation, microfiltration and 
size-exclusion-based methods (Gardiner et al., 2016).  To date, standardized 
purification methods for EV subsets isolation are not well established because EVs 
are heterogeneous in size, origin and molecular constituents. Moreover, subsets of 
EVs are overlapping in phenotype and size (Théry et al., 2018). Purification of EVs 
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from body fluids is more difficult since lipoproteins, DNA, RNA and protein 
aggregates are potential factors to contaminate EV fraction (Zaborowski et al., 2015). 
Besides, anticoagulants, temperature during isolation, freeze–thaw cycles, storage 
conditions and so on have been shown to influence the usability, vesicle purity, yield 
and components of the isolated EVs (Szatanek et al., 2015). In our study, we isolated 
EVs from melanoma cell lines HT-144 and SK-MEL-28 as well as human plasma. 
Using the established protocol (Lobb et al., 2015), we could show that our EV 
preparations fulfill the minimal requirements for EV as characterized by NTA and 
Western Blot. NTA analysis indicated that purified EVs from cell supernatants were 
mainly small particles with a diameter of approximately 100-120 nm and plasma EVs 
with peaks showed up at 140-160 nm. Besides, Western Blot analysis showed the 
expression of EV surface marker CD9, CD81 as well as the intraluminal marker ALIX. 
By checking the negative expression of calreticulin, a specific marker of the 
endoplasmic reticulum, the purity of isolated EV fraction was confirmed since the 
proteins of intracellular compartments and cell debris were excluded as possible 
contamination factors (Van Deun et al., 2014). Of note, the marker of parental cells 
gp100 was also detected in cell line-derived EVs. However, it was undetectable in 
plasma EVs from melanoma patients by Western Blot. This could be to the 
insufficient sensitivity of the detection methods, or to the low quantity of tumor-
derived EVs in the mixed EV population in circulation. Similar observation has been 
recently reported, showing that a minor portion of plasma EVs (less than 1%) derives 
directly from melanoma tissue; melanoma markers could be clearly detected on 
melanoma EVs isolated from primary melanoma cell culture but not from plasma of 
patients (Koliha et al., 2016). 
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5.2 Melanoma EVs promote survival and migration ability of monocytes 
Apoptosis is a physiological form of cell suicide, and extracellular microenvironment 
plays a crucial role in regulating apoptosis (Mangan et al., 1993). Our data provide 
evidence that CD14+ monocytes had a diminished apoptosis upon EV stimulation, 
which is in accordance with the previous findings (Valenti et al., 2006). In addition, 
we found that anti-apoptotic genes such as Bcl-2 and survivin are upregulated. 
Importantly, the expression of Bcl-2 protein was enhanced by HT-144 EVs in a time- 
and dose-dependent manner. Interestingly, previous publications showed that EVs 
purified from melanoma and colorectal carcinoma can induce FasL- or TRAIL-
mediated apoptosis in activated anti-tumor cytotoxic T and NK cells (Andreola et al., 
2002; Huber et al.,2005). It seems that tumor-derived EVs have different effect on 
apoptosis depending on the type of their target cells.  
Migration of monocytes from the bloodstream to the tumor lesion is required for 
routine immunological surveillance of tissues and their entry into inflamed sites 
(Parihar et al., 2010) (ref.). We, therefore, evaluated the migration ability of 
monocytes 3 h after the exposure to EVs. CD14+ monocytes showed enhanced 
migration in Boyden chamber assays in a dose-dependent manner. It has been 
reported that tumor-derived EVs could enhance also the migration of fibroblasts and 
further promote pre-metastatic niche formation (Becker et al., 2016). In addition, an 
enhanced migratory capacity was observed for normal human astrocytes stimulated 
with glioblastoma multiforme-derived EVs leading to enhanced cytokine production, 
which promote tumor growth (Oushy et al., 2018). Taken together, tumor derived EVs 
are able to induce the migratory behavior of immune cells or stroma cells promoting 
thereby their pro-tumor activity. 
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5.3 The change of phenotype and induction of immunosuppressive activity of 
monocytes by tumor-derived EVs 
Minimal phenotypic and functional criteria for classifying MDSCs have been recently 
suggested (Bronte et al., 2016). Although the activity of different effector cells like B 
cells (Lelis et al., 2017; Wang et al., 2018) and NK cells (Lindau et al., 2013) can be 
influenced by immune suppressor cells, inhibition of T cells is the current ‘gold’ 
standard to evaluated immunosuppressive function. We asked whether HT-144 EVs 
could convert monocytes into immunosuppressive cells and inhibit CD8+ T cells 
activated with CD3/CD28 antibodies. A significant decrease of proliferating CD8+ T 
cells and IFN-γ secretion was observed when T cells were co-cultured with 
monocytes previous stimulated with HT-144 EVs. Monocytes without EV stimulation 
showed no inhibition of T cells as well as the production of IFN-γ. Previous 
publications have shown that tumor-derived EVs could have a direct influence on T 
cells, for example inducing apoptosis of activated CD8+ effector T cells in vitro 
(Wilcox and Hirshkowitz, 2009). To get rid of the direct effect of EVs on T cells, we 
washed out the EVs from the cultured monocytes after overnight incubation. These 
findings demonstrate that melanoma EVs suppresse T proliferation and activity. 
Moreover, the phenotype of stimulated monocytes was also tested. As one of the 
most important inhibitory checkpoint molecules, PD-L1 has been supposed to play a 
crucial role in suppressing the immune system, especially T cells under pathological 
conditions. A dramatic increase of PD-L1 protein on the surface of monocytes was 
observed. Interestingly, new PD-L1 mRNA synthesis was also seen in monocytes 
stimulated with EVs derived from two different melanoma cells line. For further 
characterizing the conversion of monocytes into M-MDSCs, the expression of 
another important molecule, HLA-DR, was evaluated. We observed a slight 
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upregulation of HLA-DR on monocyte after 24 h followed by its downregulation after 
a longer exposure (48 h). Treatment with plasma-derived EVs also triggered similar 
alterations in PD-L1 and HLA-DR expression, resulting in CD14+PD-L1+HLA-DRlow 
cells, a phenotype typical for M-MDSCs. 
 
5.4 PD-L1 upregulation on monocytes by tumor-derived EVs is dependent on 
Toll-like receptor signaling pathway 
Next, we wanted to investigate the signaling pathway involved in PD-L1 upregulation. 
Various factors have been previously studied that regulated PD-L1 expression on 
immune and stroma cells (Sun et al., 2018). Among them, interferons were shown to 
stimulate the expression of PD-L1. Alternatively, LPS or miRNA that bind to the 3` 
UTR of the PD-L1 mRNA were also reported to control PD-L1 expression (Gong et 
al., 2009, 2010; Hawn and Underhill, 2005; Lu et al., 2008; Sun et al., 2018) . 
Importantly, inflammatory signaling has been shown to be involved in the 
upregulation of PD-L1 gene (Sun et al., 2018). In our study, we observed that PD-L1 
can be highly upregulated on the surface of normal monocytes upon the stimulation 
of the TLR2 agonist Pam3/CSK4 and the TLR4 agonist LPS. Surprisingly, the effect 
of tumor-derived EVs on PD-L1 upregulation on monocytes was almost as strong as  
those agonists. Using TLR blocking antibodies, we could confirm the involvement of 
TLR signaling, especially TLR4, in controlling PD-L1 expression by tumor-derived 
EVs. Previous study showed that bone marrow progenitor cells from mice could be 
induced by LPS to develop into MDSC cells, both in vivo and in vitro, which also 
strongly proved the importance of TLR4 signaling in the MDSC induction (Tu et al., 
2008). 
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Huber et al. (2018) have recently described that the conversion of monocyte into 
MDSCs was mediated by tumor-derived miRNAs. It was  further indicated that the 
miR signature (miR-146a, miR-100, miR-125b, and miR-155) carried by melanoma 
EVs was associated with resistance to immune checkpoint inhibitors in melanoma 
patients (Huber et al., 2018). However, miRNA-155 was also shown to be strongly 
upregulated upon IFN-γ and TNF-α treatment in endothelial cells and fibroblasts (Yee 
et al., 2017). miRNA-155 could bind to PD-L1 3′-UTR and suppress the expression of 
PD-L1 miRNA-155 induction via TNF-α and IFN-γ suppresses expression of PD-L1 in 
human primary cells (Yee et al., 2017). Moreover, noncoding Y RNA hY4 may serve 
as a driver for PD-L1 upregulation upon the treatment with exosomes from plasma of 
CLL patients which involves the TLR (Haderk et al., 2017). Our finding represented 
one of the likely mechanisms involved in immunosuppression mediated by EV. 
However, more TLR signaling pathways should be further investigated. 
5.5 Inflammatory pathway is induced in circulation monocytes by tumor-
derived EV 
Monocyte activation is controlled by different transcription factors. Among them, NF-
κB was shown to be crucial in regulating inflammatory gene expression as well as the 
accumulation and function of MDSC, mainly M-MDSC (Condamine and Gabrilovich, 
2011). Moreover, TLR family plays a prominent role in NF-κB activation (Condamine 
and Gabrilovich, 2011). In our study, an increase of NF-κB activity was observed 
upon tumor-derived EV stimulation. Besides, the observed upregulation of pro-
inflammatory (like IL-6, IL-1β, TNF-α and CCL-2) and anti-inflammatory factors IL-10 
was in line with the induction of NF-κB. Moreover, the application of NF-κB inhibitor 
led to partial abrogation of the PD-L1 upregulation. 
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In addition, NF-κB is also known to be a key regulator of apoptosis (Fan et al., 2008).  
It was found that the pro- or anti-apoptotic function of NF-kB was determined by the 
nature of the apoptotic stimulus (Kaltschmidt et al., 2000). Here, we provided 
evidences that HT-144 EVs could deliver an anti-apoptotic stimulus on circulating 
monocytes that involved NF-kB activation. 
 
5.6 HSP86 as major player on EVs from melanoma cell lines and patients for 
PD-L1 upregulation and immunosuppression 
Given the results showing that TLR signaling especially TLR4 was highly involved in 
the upregulation of PD-L1 on monocytes by HT-144 EVs, we addressed the question 
about the possible ligand for TLR4 signaling activation. It is well known that HSP 
families are widely expressed on EVs (Maas et al., 2016). Moreover, HSPs like 
HSP27, HSP70, HSP90, HSP110 can interact with TLRs (Asea A, 2008; Higashikuni 
et al., 2013; Hutchinson et al., 2009; Jin et al., 2014).  Interestingly, it has been 
recently demonstrated that HSP90 inhibitors are promising candidates for combined 
immunotherapy of melanoma (Mbofung et al., 2017). Through a screen of 850 
bioactive compounds, HSP90 inhibitors 17-DMAG, BIIB021 and 17-AAG showed 
increased sensitivity of human melanoma cells to T cell-mediated killing. Moreover, in 
vivo experiments also indicated that response to anti-CTLA4 or anti-PD1 therapy was 
enhanced with the application of HSP inhibitor ganetespib (Mbofung et al., 2017). On 
the other hand, in the study of Chalmin et al. (2010), HSP72 on tumor-derived 
exosomes was demonstrated as the main driver of the suppressive activity of 
MDSCs via the activation of the TLR2/STAT3 pathway. Furthermore, a reduced 
phosphorylation of Stat3 in MDSC, leading to the inhibition of their function, was 
observed in patients with colorectal metastatic cancer 3 weeks after the application of 
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dimethylamiloride (Chalmin et al., 2010) which is known to reduce the release of 
exosome (Iero et al., 2008; Savina et al., 2003).  Our data provided evidences that 
HSP86 on tumor-derived EVs may represent a crucial molecule to regulate PD-L1 
expression on monocytes. More importantly, the acquisition of monocyte 
immunosuppressive functions was found to be dependent on HSP86 concentration. 
Taken together, these data indicated the role of HSPs in mediating an 
immunosuppressive TME and converting monocytes into MDSCs. 
 
5.7 EVs from plasma of responders and non-responders undergoing anti-PD1 
treatment show different activity on monocytes  
It has recently been reported that PD-L1 expression on EVs isolated from plasma of 
head and neck cancer patients could induce T cell dysfunction directly (Theodoraki et 
al., 2018). In our study, we raised the question if EVs from plasma of melanoma 
patients with different responsiveness to the treatment with negative check point 
inhibitors could display different effects on normal monocytes. We purified circulating 
EVs from responders and non-responders and cultured them with monocytes 
isolated from healthy donors. Interestingly, non-responder EVs showed a strong 
upregulation of PD-L1 and a moderate downregulation of HLA-DR expression. 
Moreover, monocytes stimulated with those EVs were able to inhibit the proliferation 
of CD8+ T cells and IFN-γ production of these cells. In contrast, EVs from responders 
failed to induce PD-L1 upregulation and the acquisition of immunosuppressive 
properties by monocytes. Furthermore, non-responder EVs showed higher 
expression of HSP86 compared to responder EVs. These results are consistent with 
our previous finding of monocyte-mediated immunosuppression upon the treatment 
with EVs from HT-144 melanoma cells. However, due to the limited patient numbers, 
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a definitive conclusion cannot be made. A larger cohort of melanoma patients under 
an anti-PD-1 therapy should be tested, and the expression of HSP86 on EVs of 
patients from responders and non-responders should be monitored before and after 
therapy.  
Of note, although tumor cells may not be the only source of EVs collected from 
patients’ plasma, the detrimental effect on differentiating monocytes into M-MDSC 
was exclusively induced by EVs purified from non-responders and not from 
responders. 
 
5.8 PD-L1 on monocytes as potential predictive marker for responsiveness of 
anti-PD1 therapy in melanoma patients  
Next, we tested the PD-L1 expression on circulating monocytes from responders and 
non-responders, considering that those monocytes were consistently under the 
influence of circulation EVs in plasma. PBMCs from 30 melanoma patients under 
anti-PD-1 therapy were collected. A significant decrease of PD-L1 on monocytes was 
observed in responders after the first infusion of anti-PD-1 antibodies as compared to 
the basal levels. In contrast, no changes were seen in non-responders. Moreover, 
melanoma patients with low PD-L1 expression on monocytes had a significantly 
better overall and progression free survivals.  It has previously been demonstrated 
that PD-L1 expression on tumor cells plays an important role in preventing T cell-
mediated anti-tumor activity and could be used for prediction of the efficiency of anti-
PD-1 therapy (Blank et al., 2005; Iwai et al., 2002). In a randomized, phase 3 study 
where 834 patients with advanced melanoma were recruited 
for pembrolizumab therapy, a clinical benefit of pembrolizumab over ipilimumab was 
observed in both PD-L1–positive and PD-L1–negative subgroups (Robert et al., 
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2015). Moreover, accumulating data from preclinical and clinical studies 
demonstrated the importance of PD-L1 on myeloid cells for PD-1/PD-L1 blockade-
mediated tumor regression (Tang et al., 2018). In clinical study, it was shown that the 
frequency of CD14+CD16−HLA-DRhi monocytes was a strong predictor of progression 
free and overall survival upon anti-PD-1 immunotherapy (Krieg et al., 2018). Our data 
suggest that the change of PD-L1 expression on monocytes after first application of 
anti-PD1 therapy could predict the responsiveness of melanoma patients to this 
therapy.  
 
5.9 Conclusion 
Taken together, our results demonstrate the importance of tumor-derived EVs in the 
induction of immunosuppression by converting normal monocytes into M-MDSCs 
resulting in inhibition of T cell-mediated antitumor immunity. HSP86 was shown to be 
the main driver for this conversion. Moreover, EVs isolated from non-responding 
melanoma patients treated with anti-PD-1 antibodies displayed higher HSP86 
expression and showed similar immunosuppressive effects on monocytes as those 
mediated by EVs purified from melanoma cell lines. Furthermore, our study offers a 
rationale for using the measurement of PD-L1 expression on circulating monocytes 
as a predictive marker for the clinical outcome of anti-PD-1 therapy. Further studies 
with larger patient cohorts involving pre/post therapy assessments of HSP86 on EVs 
are needed to further validate their potential role as a reliable predictive marker. 
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6 SUMMARY 
The aim of the study was to investigate the role of extracellular vesicles (EVs) 
derived from human melanoma cell lines as well as from plasma of melanoma 
patients in conversion of circulating CD14+ monocytes into monocytic myeloid-
derived suppresser cells (M-MDSCs). We demonstrated that EVs purified from 
melanoma cell line HT-144 (HT-144 EVs) showed an anti-apoptotic effect on CD14+ 
monocytes via the upregulation of Bcl-2 at the mRNA and protein level. Moreover, 
CD14+ monocytes showed a modulation in inflammatory gene expression as well as 
an enhanced migration activity upon HT-144 EV stimulation. Furthermore, 
upregulation of PD-L1 and downregulation of HLA-DR was observed in monocytes 
upon the treatment with EVs from HT-144 and another melanoma cell line SK-MEL-
28, which confirmed the change of phenotype from classical monocytes to M-
MDSCs. Importantly, the stimulated monocytes showed a strong immunosuppressive 
activity by inhibiting CD8+ T cell proliferation and the production of IFN-ү. The 
upregulation of PD-L1 was induced via Toll-like receptor (TLR) signaling pathway, 
including TLR2 and TLR4, where TLR4 showed a prominent role. NF-B was 
activated, which led to the upregulation of PD-L1. The blockage of TLR4 with anti-
TLR4 blocking antibody or NF-B with an NF-B inhibitor significantly diminished PD-
L1 upregulation. We also found that HSP86 was expressed on EVs from melanoma 
cell lines. By comparing monocytes stimulated with HSP86+ EVs with those from 
HSP86low/- EVs of HT-144 cells, we observed an abrogation of PD-L1 upregulation 
and immunosuppressive activity. Besides, we tested the expression of HSP86 on 
plasma EVs from melanoma patients responding and non-responding to anti-PD-1 
therapy. We demonstrated that EVs from non-responders upregulated PD-L1 
expression and induced immunosuppressive activity of circulating monocytes, 
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converting them into M-MDSCs. In addition, those EVs displayed higher HSP86 
expression as compared to non-responder EVs. Finally, we studied PBMCs from 30 
melanoma patients before and after anti-PD-1 therapy and found a significant 
decrease of PD-L1 expression in circulating monocytes from responders as 
compared to the level before therapy. Moreover, patients with lower PD-L1 
expression on circulating monocytes showed better overall and progression free 
survival. Taken together, our finding demonstrated a crucial role of tumor-derived 
EVs in converting circulating monocytes into M-MDSCs and the importance of PD-L1 
expression on monocytes in melanoma patients undergoing anti-PD-1 therapy for the 
prediction of therapy responsiveness.   
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7 ZUSAMMENFASSUNG 
Das Ziel dieser Studie war es die Rolle von extrazellulären Vesikeln (EVs) bei der 
Umwandlung von zirkulierenden CD14+ Monozyten in monozytäre myeloide 
suppressor Zellen (M-MDSCs) zu untersuchen. Dabei wurden EVs aus humanen 
Melanomzelllinien, sowie Plasma von Melanompatienten isoliert. Wir haben gezeigt, 
dass EVs von HT-144 Zellen (HT-144 EVs) Bcl-2 in CD14+ Monozyten 
hochregulierten (auf mRNA -und Proteinebene) und dieses eine anti-apoptotische 
Wirkung hatten. Darüber hinaus zeigten CD14+ Monozyten ein verstärktes 
Entzündungsprofil, sowie eine verstärkte Migration nach der Stimulation mit HT-144 
EVs. Nach der Behandlung der Monozyten mit EVs aus HT-144 und SK-MEL-28 
Zellen, wurde ein Hochregulation von PD-L1 und eine herunter Regulierung von 
HLA-DR auf Monozyten beobachtet. Dieser Phänotyp bestätigte die Konvertion von 
klassischen Monozyten zu M-MDSCs. Die stimulierten Monozyten zeigten eine stark 
immunsuppressive Aktivität, da diese die Proliferation von CD8+ T Zellen, sowie 
deren Produktion von IFN-ү unterdrückten. Die Hochregulation von PD-L1 wurde 
über den Toll-like-Rezeptor (TLR)2 und TLR4 Signalweg induziert, wobei TLR4 eine 
dominantere Rolle spielte. Der Signalweg aktivierte NF-B, was zur Hochregulation 
von PD-L1 führte. Die Blockade von TLR4 mittels TLR4-blockierenden Antikörpern, 
sowie NF-B mit NF-B Inhibitoren verringerte die PD-L1 Expression signifikant. Des 
Weiteren fanden wir, dass auf EVs von Melanomzelllinien HSP86 exprimiert wurde. 
Der Vergleich von HSP86+ EVs mit HSP86low/- EVs verdeutlichte die Bedeutung von 
der HSP86 vermittelten PD-L1 Expression und der immunsuppressiven Aktivität. 
Zudem haben wir die Expression von HSP86 in Plasma EVs von Melanompatienten 
getestet, welche eine Anti-PD-1 Therapie erhielten. Wir haben gezeigt, dass EVs von 
Nicht-Respondern die PD-L1 Expression hochregulierten und eine 
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immunsuppressive Aktivität in zirkulierenden Monozyten induzierten. Diese EVs 
zeigten zusätzlich eine deutlich höhere Expression von HSP86 im Vergleich zu EVs 
von Respondern. Schließlich untersuchten wir PBMCs von 30 Melanompatienten vor 
und nach einer Anti-PD-1 Behandlung. Wir fanden eine signifikante Abnahme der 
PD-L1-Expression in zirkulierenden Monozyten von Respondern im Vergleich zum 
Beginn der Therapie. Darüber hinaus zeigten Patienten mit niedrigerer PD-L1 
Expression auf zirkulierenden Monozyten besseres progressionsfreies Überleben. 
Zusammengefasst demonstrieren unsere Ergebnisse eine bedeutende Rolle von 
Tumor-EVs bei der Umwandlung von zirkulierender Monozyten in M-MDSCs. Des 
Weiteren konnten wir zeigen, dass die PD-L1 Expression auf Monozyten bei 
Melanompatienten, welche sich einer Anti-PD-1 Therapie unterziehen, eine 
entscheidende Rolle bei der Vorhersage des Therapieerfolgs hat. 
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